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1.1 Chronic kidney disease
1.1.1 Definition
A wide range of disorders can induce chronic kidney disease (CKD) and affect kidney structure
or/and function in a long term [1]. According the definition of CKD in KDIGO 2012, over 3
months of abnormal manifestations in kidney structure or function is defined as CKD [1]. So
far the indication of kidney structural and functional abnormalities is based on various
assessments. According to KDIGO 2012, the indication includes reduced glomerular filtration
rate (GFR) (<60 ml/min/1.73²), structural changes diagnosed by imaging or histology, kidney
transplantation, increased urine albumin excretion, aberrant urinary sediment, and
electrolyte, water, acid-base imbalance as a consequence of various tubular disorders [1].
1.1.2 Classification
As CKD population contains a highly heterogeneous group of individuals in terms of primary
diseases and kidney damage status, the risks of adverse outcomes, such as cardiovascular
diseases, kidney disease worsening, or progression to kidney failure, also differs accordingly
[2]. KDIGO recommends to classify CKD by the cause, urine albumin excretion, and GFR levels
[1]. In general, the risks of major outcomes increases with the increase of urine albumin
excretion rate and GFR loss, as shown in Figure 1.1. The causes of CKD also have a profound
effect on prognosis. For instance, a patients with CKD G3 due to diabetes might have a higher
risks of adverse events than a patient with CKD G4 due to tubulointerstitial disease [2]. When
a patient enters CKD G5 or requires kidney replacement treatment (KRT) such as dialysis or
transplantation, this stage is termed as kidney failure with replacement therapy (KFRT) [3].
1.1.3 The burden of chronic kidney disease
The wide prevalence, high mortality and morbidity rate, and high cost of KRT has made CKD a
great burden for public health. The worldwide population affected by CKD is large and
continues growing. It is estimated that in 2017 there were 843.6 million individuals with CKD,
accounting for 11.1% of world’s population. Meanwhile around 3.9 million patients received
KRT worldwide [4]. A study estimated that the number of individuals receiving KRT will reach
5.44 million by 2030 [5]. Besides, CKD contributes substantially to global mortality and
morbidity [6]. It is also an independent risk factor for cardiovascular disease [7]. In 2017,
around 4.5% of death was due to CKD or CKD-related cardiovascular disease [6]. Further, the
cost for KRT is high and causes a great economic burden to the society [8]. It is estimated that
in 2010, around 2.6 million patients received KRT while at the same time there were almost
an equivalent number of patients (2.3 million) did not have accessibility to KRT [5].
1
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Figure 1.1: A classificationof CKDprognosis depending onGFRandurine albumin excretion. This heatmap shows
the CKD prognosis classification. CKD risk is classified into low (green color), moderate (yellow), high (orange),
and very high (red) dependent on GFR (G1-G5) and ACR (A1-A3) categories. CKD, chronic kidney disease. GFR,
glomerular filtration rate. ACR, albumin-creatinine ratio. Adapted from [1].
1.1.4 Diabetes in chronic kidney disease
The past decades, the prevalence of diabetes mellitus (DM) has increased markedly and this
growing tendency will continue in the following decades [9]. It is estimated that in 2017, 8.4%
adults (451 million adults) had DM globally. The estimated number of diabetic individuals by
2045 is projected to 9.9% of the global population (693 million) [9].
As DM is one of the most common causes for CKD [10, 6], the prevalence of DM also
increases the burden of CKD [6]. Of all the DM categories, type 2 diabetes (T2D)
predominantly represents 90 to 95% of those with diabetes [11, 12]. In 2017, DM was
attributed to around 30% of CKD-related disability, ranking as the largest contributor than any
other causes [6]. Compared to patients with non-diabetic kidney diseases, CKD patients with
diabetes have higher risks of developing cardiovascular disease and progression to KFRT [13].
Thus, there is a great unmet medical need to improve outcomes for CKD with diabetes.
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1.2 Diabetic kidney disease
1.2.1 Natural history
The nature history of diabetic kidney disease (DKD) was described by Mogensen CE, et al. in
the 1980s. In this classic description, which was mainly based on proteinuria progression
among patients with type 1 diabetes (T1D), it illustrated a 5-stage DKD: early
hypertrophy-hyperfunction, glomerular lesions without clinical disease, incipient DKD with
microalbuminuria (15-300 µg/min) and normal GFR, overt DKD with persistent proteinuria
(>0.5 g/day) and declined GFR, and KFRT [14]. This concept evolved due to the heterogeneity
of DKD phenotype on the basis of albuminuria and GFR, which are the most prominent
markers in predicting risk of KFRT and renal death [15, 16, 17]. For instance, the NEFRON
study collected data from 3893 patients with T2D and found of the 48.1% diabetic patients
with CKD, only 10% exhibited albuminuria and reduced GFR, 20% exhibited only mildly
increased albuminuria, 4.1% exhibited only moderately increased albuminuria, and 12.4%
exhibited reduced GFR and normal albuminuria [15]. As shown in Figure 1.2, in a classic
phenotype, whole-kidney GFR level increases in the early stage, then drops to normal level,
and continuously declines. Microalbuminuria appears in the hyperfiltration stage and
progresses to macroalbuminuria as GFR declines. In non-classic phenotypes, total kidney GFR
declines before the onset of macroalbuminuria or even microalbuminuria. Notably, here total
kidney GFR refers to the filtration level as a whole organ or the sum of all single-nephron GFR.
Total kidney GFR and single-nephron GFR do not always match. For example, in the early
stage of DKD, sodium-glucose cotransporter (SGLT)-mediated dysfunction of
tubular-glomerular feedback results in an increase in single-nephron GFR as well as
whole-kidney GFR if the total nephron number remains similar. As DKD progresses and total
kidney GFR declines but single-nephron GFR increases as less and less nephrons have to
handle the same filtration load [15].
Figure 1.2: Evolution of kidney function in diabetic kidney disease. Increased and subsequent decrease
of glomerular filtration rate in patients with proteinuria (classic phenotype), microalbuminuria, and
normoalbuminuria (the latter two, non-proteinuric phenotype). Adapted from [16].
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1.2.2 Hemodynamic alterations
As mentioned before, a typical GFR evolution in DKD is characterized by an increased
whole-kidney GFR in the early phase. After the GFR reaches the maximum, it starts to decline,
in parallel with nephron loss [17]. There are at least two distinct elements contributes to
hyperfiltration [18, 17]. One is due to nephron loss, the remnant nephron undergoes
structural and function changes, resulting in hypertrophy and single-nephron hyperfiltration,
as shown in Figure 1.3. By using this strategy, kidneys try to compensate the loss of nephrons,
and to maintain overall filtration and absorption levels [18, 17]. The other element is that
diabetic conditions (hyperglycaemia, hormones, metabolites), as well as obesity, promote
hyperfiltration [17]. How diabetic conditions drive hyperfiltration may comprise several
mechanisms and is still not fully understood. One major mechanism is abnormal
tubuloglomerular feedback [18, 17]. After glucose passes through glomerular basement
membrane (GBM), it is reabsorbed together with sodium at 1:1 ratio via SGLT1/2 at proximal
tubule cells [19]. In diabetic patients, excessive glucose filtration causes excessive glucose and
sodium reabsorption at proximal tubules. Therefore, less sodium is transported to the distal
tubular lumen at the macula densa. In response to the reduced sodium level in the tubular
lumen, the macula densa produces less adenosine. Less adenosine activity at the afferent
arteriole leads to vasodilation and increased GFR [19].
Figure 1.3: Schematic drawing of nephron loss in diabetic kidney disease. In individuals with hyperglycemia,
elevated blood glucose and SGLT2-mediated tubuloglomerular feedback disorder increase the single nephron GFR
and total kidney GFR, as well as the size of all glomeruli (hypertrophy). As the disease progression continues, some
nephrons undergoes sclerosis and lost function. The remnant nephrons attempt to compensate the nephron loss
andundergo further hyperfiltration andhypertrophy, which accelerates the nehphron loss. SGLT2, sodium-glucose
transport protein 2; GFR, glomerular filtration rate.
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1.2.3 Structural alterations
The structural changes in DKD is shown in Figure 1.4. In early stage, the thickness of
basement membrane in GBM, tubules, and capillaries increases [20]. Podocytes flatten and
undergo foot process effacement [21]. The mesangium expands diffusely due to an
accumulation of extracellular material and cells [22]. Glomeruli increase in size [22]. As
disease progresses, nodular mesangial expansion, also called Kimmelstiel-Wilson lesions,
localize to the mesangium. There are round-shaped lesions with an acellular matrix core and
few crescent-shaped nuclei around the periphery. Under scanning electron microscope, the
glomerulus of nodular sclerosis site shows a nude and smooth GBM with few or no podocyte
coverage [21]. In the more advanced phase, diffuse and nodular expansion leads to
glomerulosclerosis. Glomeruli lose functional podocytes and are filled with matrix
components [23]. Apart from alteration in glomerular tufts, the Bowman’s capsule thickens,
and occasionally displays a so-called insudative lesion, characterized by forming a ”bridge”
between capsule and glomerular tuft. Arteries, arterioles, and glomerular capillaries undergo
hyalinosis as a result of deposition of plasma proteins and lipids [22]. Interstitial fibrosis and
tubular atrophy follow the alteration in glomeruli. Infiltrated immune cells are present in
glomeruli and interstitium [22, 24].
Figure 1.4: Schematic drawing of glomeruli in healthy conditions and diabetic kidney disease. In diabetic
kidney disease (left), glomerular volume increases. Immune cells infiltrate to glomeruli as well as interstitium.
Excessive mesangial cells, matrix, and immune cells accumulate in mesangial area. Podocyte undergoes foot
process effacement and detachment. Interstitium undergoes fibrosis. Modified from reference [25].
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1.2.4 Role of inflammation in diabetic kidney disease
A wide range of evidences suggest inflammation is a pathomechanistic contributor to the
development of DKD [26, 27, 28]. Apart from the well-documented role of inflammation in
established DKD, such as infiltrating immune cells [22] and upregulation of pro-inflammatory
mediators [27], some evidences suggest that inflammation may also contribute to the
initiation of DKD. One recent publication reviewed 31 urine proteomic/peptidomic studies
and summarized robust urine markers in each stage of DKD. It showed that in early stage of
DKD, when albuminuria was absent, inflammatory mediators such as α1-antitrypsin and
clusterin, appeared in the urine, reflecting an early inflammation activity in kidney [29].
The mechanism by which inflammation leads to the initiation and progression of DKD is
complicated and still not fully understood. Recently, Monika A.N., et al. analyzed 194
circulating inflammatory proteins by proteomics in diabetic patients with early or advanced
DKD, and identified 17 inflammatory cytokines/proteins which were associated with a 10-year
risk of KFRT, suggesting circulating cytokines/proteins contributes to kidney disease
progression in DKD [30]. Of the 17 inflammatory cytokines/proteins, most were expressed by
kidney infiltrating monocytes/macrophages and T cells, as confirmed by another single-nuclei
sequence study, highly suggesting a causal role of infiltrated immune cells in pathogenesis of
DKD [31]. Thus, systemic inflammation, either by circulating cytokines/proteins or by immune
cell infiltration, may contribute to the initiation and progression of DKD [32].
Apart from systemic inflammation, many inflammatory pathways and molecules
contribute to local inflammation in DKD (Figure 1.5). These deviations include metabolic
abnormalities (hyperglycemia, hyperlipidemia, and numerous metabolites) [33], increased
circulating inflammatory cytokines [30], hemodynamic alterations (hypertension,
hyperfiltration, increased sheer stress) [34], increased oxygen consumption and kidney
hypoxia [35, 36], and hormone dysregulation such as increased synthesis of angiotensin II
[13]. These deviations act on almost all parenchymal cells of the kidney, such as podocytes,
endothelial cells, tubular epithelial cells, and mesangial cells, and some non-parenchymal
cells such as macrophages/dendritic cells. In some circumstance, dead cells or impaired cells
release danger-associated molecular patterns (DAMPs) [37], which bind to pattern recognition
receptors (PRRs) and activate proinflammatory signal pathways and transcript factors, like
JAK-STAT and cytokine-dependent nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB), and increase the expression and secretion of proinflammatory cytokines [27].
The Evidence from pharmacological blockade or genetic loss in animal models of DKD have
identified numerous proinflammatory cytokines as contributors to structural and functional
alterations in DKD, such as interleukin-1β (IL-1β) [38], IL-6 [39], and tumor necrosis factor α
(TNFα) [40, 41, 42]. The mechanism by which these cytokines lead to kidney impairment may
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Figure 1.5: Inflammatory mechanisms and pathways leading to DKD. RAAS, renin-angiotensin-aldosterone
system. RAGE, receptor for advanced glycation end products. NADPH, nicotinamide adenine dinucleotide
phosphate. ROS, reactive oxygen species. AGE, advanced glycation end-products. NK-κB, nuclear factor kappa-
light-chain-enhancer of activated B cells. GBM, glomerular basement membrane. JAK, Janus kinase. STAT, signal
transducer and activator of transcription. Adapted from [27].
include oxidative stress [42, 38], inflammation amplification, such as upregulation of cytokine
receptors and proinflammatory cytokines [42, 41, 40, 39], apoptosis and necroptosis [40], and
fibrosis [43]. Proinflammatory cytokines could be novel promising therapeutic targets for DKD
[27].
Taken together, inflammation is an essential mechanism in the progression of DKD.
Cytokines releasing by numerous activated cell types in diabetes amplify kidney inflammation
and contributes to kidney structural changes and functional deterioration, thus serving as
potential therapeutic targets.
1.2.5 Current trials and new therapeutic approaches
Even though inflammation mechanism and pathways are well-identified in the past two
decades, conventional treatment for DKD, including anti-hypertension therapy,
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glucose-lowering therapy, and renin-angiotensin-aldosterone system blockade, remained
unchanged. Recently, new therapeutic agents like sodium-glucose cotransporter 2 inhibitors
(SGLT2i), have showed prominent kidney protection, as well as reduced cardiovascular events,
expanding the treatment choice for DKD. Here I briefly summarized the recent phase-3 or -4
trials, both finished or ongoing, in diabetes or DKD to have an overview of current situation of
new therapeutic approaches, as shown in Table 1.1. Notably, through the well-established
role of inflammation in DKD, the number of 3- or 4-phase clinical trials using
anti-inflammatory medicine is limited.
Sodium-glucose co-transporter 2 inhibitors
SGLT2i blocks glucose reabsorption at proximal tubules, as well as sodium reabsorption, thus
restores tubuloglomerular feedback and single-nephron GFR [18]. The EMPA-REG OUTCOME
trial found that empagliflozin had significant cardiovascular benefits in T2D patients with
established cardiovascular disease [44]. Subgroup analysis found empagliflozin was
associated with slower eGFR deterioration, slower albuminuria progression, and less incident
KFRT, indicating the kidney benefits of SGLT2i [45]. Similar results were achieved in the
CANVAS study using another SGLT2i canagliflozin [46, 47]. Diabetic patients without risks for
cardiovascular events or with early stage of CKD also benefited from SGLT2i from less heart
failure in another trial [48]. More recently, the CREDENCE trial has further expanded the
tested population to individuals with T2D and CKD G1-3 and ≥ A3 and set kidney-related
events as the primary outcome. They found that canagliflozin prevented adverse kidney
outcomes by 30%, a direct evidence showing the kidney protective effects from SGLT2i [49].
The success of intervention by SGLT2i demonstrates the central role of hemodynamic factors
in the progression of DKD.
Endothelin A receptor antagonist
Another novel agent is endothelin A receptor antagonist. It blocks endothelin-1 and/or
endothelin A receptor, a pathway mediating sodium retention, fibrosis, and inflammation
[49]. In SONAR trail, atrasentan has beneficial effects on serum creatinine increasing or
progression to KFRT in CKD patients with T2D.
Glucagon-like peptide 1 analogue
Glucagon-like peptide 1 (GLP1) analogue is a class of glucose-lowering medicine. By binding
to the GLP1 receptor on β cells, it can induce the release of insulin and at the same time
inhibit the release of glucagon. It improved glycemic control and had cardiovascular benefits
in individuals with T2D and high cardiovascular risks [50, 51]. Further, in AWARD-7 trial GLP1
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analogue dulaglutide showed an protection effect on ameliorating GFR decline in diabetic
individuals with CKD G3-G4 [52].
Dipeptidyl peptidase 4 inhibitors
Dipeptidyl peptidase-4 inhibitor (DPP4i) is another glucose-lowering medication that
targeting DPP4, a protease that cleaves GLP1. Through improving glycemic control, DPP4i did
not deliver further benefits on cardiovascular outcomes in diabetic patients in trials with
cardiovascular events as primary endpoints [53, 54, 55]. A more recent cardiovascular
outcome trial CARMELINA had tested an DPP4i linagliptin in T2D patients with moderate or
high CKD risks and did not find an evidence of extra cardiovascular benefits [56].
Anti-mineralocorticoid
Anti-mineralocorticoid might be another promising agent for DKD. The PRIORITY trial tested
spironolactone in patients with T2D and normal albuminuria [57]. Notably, the trial utilized
urinary proteomics as an enrichment method to select high-risk normal-albuminuric diabetic
patients for early intervention, which was an innovation in the field of clinical trials on DKD
[57]. However, treatment with spironolactone failed to prevent albuminuria progression (ASN
Kidney week 2019). Another two Phase 3 trials on finerenone (FIGARO-DKD, FIDELIO-DKD) are
still ongoing.
1.3 Mouse models of diabetic kidney disease
1.3.1 Validation criteria
Over many years, researchers have been looking for a DKD animal model that shows
characteristic phenotypes of human DKD in an accurate manner [61, 62]. The characteristic
phenotypes include at least three aspects [61, 62]. Firstly, it should resemble the functional
features of human DKD, such as reduced GFR, elevated albuminuria, and hypertension.
Secondly, it should present similar kidney pathology to DKD patients, such as GBM thickening,
mesangial expansion or nodular lesions, glomerular sclerosis, and interstitium fibrosis. Lastly,
it should also share similar pathogenic pathways, which could be examined at transcription or
protein expression levels, or share similar metabolic profiles [61, 62]. Some researchers
proposed the goals of an acceptable DKD model [61, 62] as follows:
1. Mice have more than 50% GFR decline compared to their earlier lifetime.
2. Mice havemore than 100 times of albuminuria than their age- and sex-matched controls.
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3. Mice have following changes in kidney pathology:




To generate a DKD model, there is a variety of strategies, which can be decomposed into three
factors: diabetes platforms, susceptible strains, and accelerators [61].
1.3.2 Diabetes platforms
Diabetes platforms that build up hyperglycemia can be divided into two categories, T1D and
T2D. Commonly used models for T1D includes streptozotocin (STZ) induction (pancreatic
β-cell injury), non-obese diabetic (NOD) mice (autoimmune insulitis), Akita Ins2+/𝐶96𝑌 mice
(incorrect folding of insulin), and OVE26 mice (accumulation of camodulin in β-cell leading to
deficient insulin production). For models of T2D, db/db mice (leptin receptor deficient) and
ob/ob mice (leptin deficient) are most widely used [61, 62]. KK-A𝑦 mice are sometimes used
as an model for T2D and obesity [63]. Tn this mode, the polygenic feature comes from KK
strain. The heterozygous for yellow spontaneous mutation (A𝑦) at agouti locus contribute to
the abnormal glucose metabolism [63].
1.3.3 Genetic background and permissive strains
The severity of diabetes and kidney phenotypes can be greatly shaped by different genetic
backgrounds. For example, male DBA/2 demonstrated more robust hyperglycaemia, urine
albumin excretion and glomerular mesangial expansion with STZ than other strains like
C57BL/6, MRL/Mp, 129/SvEv, and Balbc [64, 65]. C57BL/Ks, FVB, DBA/2J, and BTBR (black and
tan, brachyuric) stains carrying db/db or ob/ob mutations exhibit more severe diabetes and
proteinuria than C57BL/6J or 129/J with the same mutation [66, 67, 68, 69]. C57BL/Ks is a
mouse stain sharing approximately 84% C57BL/6J-like and 14% DBA/2J-like alleles [70].
Notably, BTBR ob/ob mice develop severe hyperglycaemia and more profound glomerular
mesangial expansion than more commonly used C57BL/Ks db/dbmice [71].
1.3.4 Strategies to accelerate kidney disease
Various strategies have been employed to accelerate the progress of kidney disease. One is to
perform an early uninephrectomy to increase the filtration load on the remnant kidney and
speed up adaptive glomerulosclerosis similar to what happens in obesity. As endothelial
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dysfunction is a key determinant in diabetic kidney progress, the attempt to use Nos3 gene
deficiency as an approach to increase endothelial dysfunction resulted in profound
albuminuria, kidney morphology, and GFR decline in either C57BLKS/J db/db or C57BL/6 STZ
model [72, 73]. Shannon MH, et al. used adeno-associated virus delivery of renin (ReninAAV)
to superimpose hypertension in three well-built diabetes models and found ReninAAV
treatment greatly accelerated DKD [74]. Similar result was achieved by using transgenic mice
expressing active human renin in the STZ model or the OVE26mouse model [75].
1.3.5 Oxalate-rich diet as a strategy to induce chronic kidney disease
Mulay, et al. reported a convenient inducible CKD mouse model by feeding C57BL/6 mice
with soluble oxalate-rich diet [76]. Oxalate-rich diet induced ≈85% GFR loss, ≈7 times higher
level of blood urea nitrogen (BUN), ≈6 times higher levels of serum creatinine. In the kidney,
oxalate-rich diet induced progressive nephrocalcinosis, tubular atrophy, inflammation, and
fibrosis. Oxalate-rich diet also induced CKD complications, such as anemia, hyperpotassemia,
CKD-related mineral bone disease, hypertension, and cardiac fibrosis [76]. Since then this
model has been employed in numerous studies on CKD progression [77, 78, 79, 80, 81, 82].
Taken together, a reliable diabetes platform, a permissive genetic background, and
combining with one or more strategies to speed up disease progress make an animal model of
DKD more clinical relevant. A main shortcoming of the current DKD mouse models is that
disease manifestations are not severe, in many cases due to lacking strategies to accelerate
the kidney disease progression. Oxalate-rich diet induces GFR loss and CKD complications,
and could be a promising and convenient method to generate an animal model of advanced
DKD.
1.4 Interleukin-1β
As mentioned before, anti-inflammatory cytokines are promising therapeutic target for DKD.
The therapeutic role of IL-1β is of interest as IL-1β is a well-studied cytokine and contributes
to various diseases [83]. In CANTOS trial, patients treated with a monoclonal antibody
targeting IL-1β had more cardiovascular benefits than those treated with placebo, confirming
that inflammation plays a role in atherothrombosis [84]. Here I briefly summarized the
biology of IL-1β and its potential role in DKD.
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1.4.1 Biology of interleukin-1β
Discovery
In 1974, Dinarello CA, et al. characterized two distinct human leukocytic pyrogens that share
similar potencies to induce fever in rabbits. One derived from monocytes, with a molecular
weight of ≈38 kDa, and was more acidic. The other pyrogen obtained from neutrophils, with
a molecular weight of ≈15 kDa, and was more neutral [85]. In 1984 the amino acid sequences
for both acidic and neutral pyrogens were characterized from human macrophages, and these
two proteins were termed as interleukin-1α (IL-1α) and IL-1β, respectively [86].
Gene and protein expression
In human, gene IL1B encodes IL-1β. Pro-IL-1β is first produced as a 269 amino-acid precursor,
which has no bioactivity, accumulates in cytoplasm, and requires caspase-1 to catalyze it into an
active form of 153 amino acids [87, 88, 89]. Myeloid cells express IL-1β but not in a constitutive
manner [88, 83, 90]. Toll-like receptor (TLR) ligands are themostwell-known stimuli that induce
both IL-1β mRNA and protein production in monocytes [83]. Besides, upon some non-TLR
stimuli, such as hypoxia, monocytes can produce substantial IL-1β mRNA but not with IL-1β
proteins [83].
Receptors and endogenous antagonists
The receptors and antagonists for IL-1β are listed in Table 1.2 and illustrated in Figure 1.7. IL-1β
has two receptors and one endogenous antagonist. The two receptors are IL-1 receptor type I
(IL-1R1) and IL-1 receptor type II (IL-1R2). The endogenous antagonist is interleukin-1 receptor
antagonist (IL-1Ra). IL-1R1 is also the receptor for IL-1α. An IL-1β-IL-1R1 signal requires the
binding of IL-1 receptor accessory protein (IL1RAP) (also called IL-1R3), which interacts directly
with IL-1R1 but not IL-1β itself [83, 91, 92].
As shown in Figure 1.7, both IL-1R1 and IL1RAP have a Toll-IL-1 resistance (TIR) domain
in the cytoplasmic side while IL-1R2 lacks it [90]. At resting state, IL-1R1 and IL1RAP are far
apart on cell membrane. Upon the binding of IL-1β to IL-1R1, the later undergoes a structure
transformation allowing an engagement of IL1RAP to IL-1β-IL-1R1, forming a signaling trimeric
complex [91, 92]. The trimeric complex enables the approximation of TIR domains from IL-1R1
and IL1RAP, offering a docking site for the adaptor proteinMyD88 [89, 90]. MyD88 triggers the
downstream cell signals. This intracellular signaling cascades finally lead to the activation of
transcription factors, such as JNK, mitogen-activated protein kinases p38, and NF-κB [83, 88].
On the contrary to IL-1R1 which can conduct pro-inflammatory cell signal, the binding of
IL-1β to IL-1R2 converts no cell signals [83]. IL-1R2 consists a IL-1β-interaction domain at the
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Table 1.2: Receptors and antagonist for interleukin 1
Ligand Receptor Coreceptor Function
IL-1α, IL-1β IL-1R1 IL1RAP (IL-1R3) Proinflammatory
IL-1β IL-1R2 IL1RAP (IL-1R3) Antiinflammatory
IL-1Ra IL-1R1 Not applicable Antiinflammatory
Adapted from [89].
extracellular side, which is similar to IL-1R1. However, its cytoplasmic domain is short (29 amino
acids) and lacks the TIR domain to form a signaling complex to connect to Myd88 [93]. IL-1Ra
is a naturally occurring antagonist for both IL-1β and IL-1α [83].
IL-1Ra binds competitively to IL-1R1 but does not recruit accessory protein IL-1R3, thus
converting no cell signals [91].
Activation of pro-interleukin-1β
The mechanism of IL-1β activation includes caspase-1-dependent and -independent pathways
[94]. Caspase-1 requires activation by protein complexes, called inflammasomes. The
organization of an inflammasome follows a routine pattern: a sensor recruits the adaptor ASC
and further recruits the effector pro-caspase-1 [95]. So far five inflammasome sensors have
been discovered, including nucleotide-binding domain and leucine-rich repeat pyrin
containing protein-3 (NLRP3), absent in melanoma 2 (AIM2), NLRP1, NLRC4, and pyrin [95].
Of the inflammasomes, NLRP3 inflammasome is the most well-characterized in diabetes. As
shown in Figure 1.6, the NLRP3 inflammasome incorporates three elements: the sensor
NLRP3, the adaptor ASC, and the effector caspase-1 [96]. NLRP3 itself can be divided into
three domains: the PYRIN domain (PYD) at the N terminus, the NACHT domain at the middle,
and the leucine-rich repeat (LRR) at the C terminus [96]. NLRP3 undergoes structure
transformation once it senses stress signals and become active. Active NLRP3 is able to
oligomerize and several NLRP3 molecules assemble a wheel-like structure with PYD domains
at center and LRR at the periphery. Assembled PYD circles are the hubs for the recruitment of
the adaptor ASC. ASC consists of two domains for protein interaction, an PYD at the N
terminus and a caspase recruitment domain (CARD) at the C terminus [96]. ASC molecules
bind to the PYD circle by their own PYD domains, forming a helical filament connected to the
wheel-like structure assembled by NLRP3. In this helical filament structure, PYD domains are
at the inner side, while CARD domains at the outer side for the recruitment of caspase-1.
Once caspace-1 binds to this helical filament structure via the CARD domain, it firstly forms a
caspase-1 dimer (p46). Then this dimer undergoes several steps of auto-processing and finally
generates the active form of caspase-1 (p33/p10) [97]. The active caspase-1 degrades
substrates, such as pro-IL-1β [98], pro-IL-18, and pro-gasdermin D [99, 100] into active forms.
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Figure 1.6: NLRP3 inflammasome-mediated interleukin 1β activation. NLRP3, nucleotide-binding domain and
leucine-rich repeat pyrin containing protein-3. PYD, pyrin domain, LRR, leucine-rich repeat. ASC, apoptosis-
associated speck-like protein containing a CARD, also known as PYCARD. CARD, caspase activation and recruitment
domain. Adapted from [97].
Notably, caspase-1-independent pathways can also process pro-IL-1β [94]. In zymosan-
induced peritonitis, a complement-mediated inflammation, generation of mature IL-1β mainly
depends on caspase-1. While in turpentine-induced tissue necrosis, caspase-1 deficiency only
reduces 50% of mature IL-1β production, suggesting that other proteases also participates in
processing pro-IL-1β. These findings also suggest that proteases involving in pro-IL-1β are likely
environment dependent [94]. Also matrix metalloproteinases, neutrophil proteases such as
proteinase-3, granzyme A, cathepsin G are involved in processing IL-1β [101, 94].
Regulation of interleukin-1β activation
NLRP3-dependent IL-1β production is tightly regulated and typically follows two sequential
steps [96]. The first step is priming, leading to the transcription of many components,
including IL-1β and NLRP3 [102]. Activation of PRRs requires the stimulation form
pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), bacterial
lipoproteins, and viral RNA, and lead to the priming process [102]. DAMPs, specific molecules
released by damaged and dying cells such as ATP, can also lead to this priming process via
PRRs [102]. Additionally, this priming step can also be induced by NF-κB activation [103, 104].
The second step is activation of NLRP3 by various stimuli, including a wide spectrum of
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PAMPs, self-derived and foreign-derived DAMPs [96].
Besides, NLRP3-dependent IL-1β production is not always following the two-step
mechanism [96, 105]. For example, in some circumstances, TLR4-dependent LPS stimulation
alone is sufficient release IL-1β from human peripheral monocytes but not from human
macrophages [106], or human dendritic cells [106], or mouse monocytes [105], or mouse
bone marrow-derived macrophages [105].
Biological activity
Circulating IL-1β is elevated in various diseases including sepsis and burns as well as upon LPS
injection into healthy humans [107]. However, circulating IL-1β level is low compared to other
cytokines such as IL-6 and TNFα, and the possible reasons could be that pro-IL-1β mainly stays
intracellularly and that IL-1β binds to large proteins in plasma, such as IL-1R2 and
complement [107]. IL-1β has multiple biologic effects, including inducing fever, myocardial
suppression, and hypotension, increasing bone marrow cells and circulating neutrophils and
platelets, increasing hepatic acute phase protein production, increasing metastasis, increasing
sodium excretion, increasing the non-specific resistance to infections, and many others [107].
The basis for its multi-functions is that it regulates a board range of gene expression, including
many cytokines and their receptors, colony-stimulating factors, growth factors, clotting
factors, adhesion molecules, complements, extracellular matrix components,
pro-inflammatory mediators such as type-2 cyclo-oxygenase, type-2 phospholipase A2,
endothelin-1, and inducible nitric oxide synthase, oncogenes, and others [107].
1.4.2 Roles of interleukin-1β in diabetic kidney disease
Interleukin-1β expression and activation
Diabetes-related conditions can act as a stimulus inducing inflammasome priming in immune
cells. Lee HM, et al. isolated peripheral blood mononuclear cells (PBMCs) from patients newly
diagnosed with diabetes and differentiated these cells into macrophages. Without priming,
thesemacrophages already exhibited an elevatedmRNA and protein expression of NLRP3, ASC,
and IL-1β than cells from healthy controls [108]. Upon stimulation with LPS and some DAMPs,
patient-derived macrophages produced and released more mature IL-1β. Furthermore, after
these patients received metformin treatment and their blood glucose levels were normalized,
PBMCs-derived and LPS-primedmacrophages from the samediabetic patients showed reduced
mature IL-1β release after the same stimulations [108]. This study confirmed the activation of
IL-1β in circulating immune cells in diabetes ex vivo and demonstrated that factors affected by
metformin treatment, most probably hyperglycemia, are associatedwith IL-1β activation [108].
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IL-1β level in the circulation, as well as in the urine, are increased in DKD patients with
albuminuria [38, 109]. Another interesting finding is that diabetic patients with higher
circulating IL-1R1 levels were more likely to develop KFRT in a proteomic study including three
different cohorts with T1D and T2D [30]. However, the source of circulating IL-1R1, as well as
its association to IL-1β activity and kidney function, remains unknown.
In kidneys from DKD patients, protein expression level of IL-1β is uncertain. However,
increased expression of its upstream molecules was found in human kidney in diabetes.
Immunostaining showed increased NLRP3 expression in glomeruli from DKD patients. DKD
patients also showed elevated expression levels of NLRP3, PYCARD, and CASP1 in glomerular
compartment [110]. Protein expression level of AIM2, another upstream molecule of IL-1β,
was increased in leukocytes and tubular cells in kidney biopsies from DKD [110]. For animal
models of DKD, db/db mice and streptozotocin (STZ)-treated C57BL/6 mice produced more
mature IL-1β in kidneys and the expression of IL-1β paralleled with disease progression [38,
111].
Even though traditionally IL-1β is believed to be expression by myeloid cells, some in vitro
studies also demonstrated kidney cells, such as podocyte [38, 38], glomerular endothelial
cells [38], tubular cells [112, 113, 114], were capable to express IL-1β under diabetes-related
stimulation. However, it remains controversy [115].
Together, circulating monocytes are a likely source of IL-1β release inside the kidney in
DKD. In kidney tissues of DKD, it was not clear whether parenchymal cells also release IL-1β.
Interleukin 1 blockade in functional studies
Treatment with IL-1Ra (anakinra) ameliorated the proteinuria andmesangial expansion in both
db/db mice and STZ models [38], suggesting an involvement of IL-1α/IL-1β/IL-1R axis in DKD
initiation [38].
Targeting upstream of IL-1β also showed kidney protective effects. Shahzad, K, et al.
found that global depletion of Nlrp3 or Casp1 showed kidney protection in
uninephrectomized STZ-induced mouse model [38]. Also, diabetic mice treated with
caspase-1 inhibitor showed reduced albuminuria, less fractional mesangial area, and lower
plasma IL-1β levels. Above observations suggests the involvement of NLRP3/caspase-1
activation in the pathogenesis of DKD [111]. But it was not sure whether the kidney benefit
was through blocking NLRP3/caspase-1 on myeloid cell or/and kidney parenchymal cells. The
authors further transplanted wild type, Casp1−/−, or Nlrp3−/− bone marrow cells to db/db
mice. They found that these three groups of db/db mice had comparable albuminuria and
mesangial expansion, suggesting the kidney benefit of Nlrp3 and Casp1 global knockout
derives from kidney parenchymal cells but not myeloid cells [38].
18 CHAPTER 1. INTRODUCTION
Figure 1.7: Selected actions of interleukin 1β related to diabetic kidney disease. IRAK, Interleukin-1 receptor-
associated kinase. TRAF6, tumor necrosis factor receptor associated factor 6. JNKs, c-Jun N-terminal kinases.
MAPK, mitogen-activated protein kinase. CCL2, chemokine ligand 2. Partially adapted from [116]
Thus, IL-1 blockade, as well as targeting the pathways upstream of IL-1β, has kidney
benefits in animal models of early phase of DKD.
Possible mechanisms leading to interleukin-1β activation
The possible mechanisms leading to IL-1β activation in diabetes include
hyperglycaemia-induced mitochondrial reactive oxygen species (ROS) generation. In
PBMC-derived macrophages isolated from diabetic patients, the production of IL-1β was
associated with elevated blood glucose levels and mitochondrial ROS production [108]. It was
thought that enhanced glucose influx, as well as stimulation of advanced glycation end
product via RAGE, induced mitochondrial ROS generation and the latter contributed to
ROS-dependent NLRP3 and IL-1β activation [38, 117]. The mechanism by which the NLRP3
inflammasome senses mitochondrial ROS involves thioredoxin-interacting protein-dependent
NLRP3 activation [117]. Thioredoxin-interacting protein is up-regulated when ROS is
over-produced [118]. It activates NLRP3 and inhibits antioxidant thioredoxin, making it a
pro-inflammatory molecule and a promoter for oxidative stress [117, 118]. Application of
antioxidants reduced ROS production and NLRP3-dependent IL-1β generation in cultured
podocytes and mesangial cells [38, 117]. Either using antioxidant or gene modification to
reduce ROS production showed reduced NLRP3-dependent IL-1β release and kidney
protective effects in diabetic mouse model [38].
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ATP might be another stimulus of NLRP3-dependent IL-1β activation in DKD. Extracellular
ATP binds to P2X receptors, leading to NLRP3 activation and IL-1β release. P2X expression
was upregulated in tubule epithelial cells in patients with DKD. Treatment with apyrase can
inhibit high glucose-induced NLRP3 up-regulation and IL-1β release in HK-2 cells by consuming
extracellular ATP [109]. Hyaluronan is also an endogenous trigger of NLRP3-dependent IL-1β
[119]. Elevated glucose induced proximal tubular cell hyaluronan generation in vitro [120].
After all, consistent with the introduction in 1.2.4, triggers in diabetes scenario, such as
ROS and ATP, seem to induce IL-1β activation. It is not clear whether it also involves other
mechanisms.
1.4.3 Clinical trials using interleukin-1β blockade
Searching for the intervention studies, which tested IL-1β blockade in patients with T2D using
the ClinicalTrial.gov database (keyword ”interleukin 1” together with ”type 2 diabetes”, by 21-
09-2019) retrieved 16 relevant studies as listed in Table 1.3. Seven different IL-1β inhibitors
were used: 1. Anakinra, a recombinant nonglycosylated protein similar to human IL-1Ra, 2.
CYT013-IL1bQb, a vaccine consisting a recombinant IL-1β encapsulated in virus-like particles,
3. AC-201, an oral IL-1 modulator inhibiting the activation of IL-1 via interfering with MAPK
signaling pathways, 4. Diacerein, a small molecule that inhibits IL-1β secretion and function, 5.
Canakinumab, 6. Gevokizumab, and 7. LY2189102, all recombinant, human anti-human-IL-1β
monoclonal antibodies.
The anti-diabetic effects of IL-1β blockade in T2D patients were not consistent. As shown
in Table 1.3, anakinra [121], AC-201, and diacerein [122] reduced hemoglobin A1C (HbA1c)
levels. LY2189102 showed modest effects on improving HbA1c but not on fasting glucose
[123]. In the canakinumab trial which enrolled 556 patients, however, a 4-month course of
monthly canakinumab did not improve glucose control or insulin secretion [124].
Gevokizumab also did not affect glucose control after a treatment duration of 6 months in a
trial of 421 patients. In the CANTOS trial, canakinumab did not reduce incident diabetes
among patients with prior myocardial infarction, higher levels of high-sensitivity C-reaction
protein (hsCRP), and normoglycemia; it reduced HbA1c levels only over the first 6-9 months
but this effect was attenuated over time [125]. Although effects on glucose control were not
consistent, IL-1β blockade reduced levels of various inflammation surrogates, including CRP
[121, 124, 123, 125] and IL-6 [121, 124, 123]. On patient outcomes, canakinumab reduced
cardiovascular events. This benefit might be independent from diabetes [125]. No study used
kidney-related events as endpoint.
Searching trials which tested IL-1β blockade in patients with kidney disease on
ClinicalTrial.gov database by using keywords ”interleukin 1” and ”kidney”. By 21-09-2019,
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there had been four relevant studies listed in the database (Table 1.4). Two IL-1β inhibitors
were used: anakinra and rilonacept (a recombinant protein consisting of domains of IL-1R1,
IL-1RAP, and the Fc region of human IgG1). No study used kidney-related events as endpoints.
Rilonacept improved brachial artery flow-mediated dilation and reduced inflammatory
marker expression in a cohort with 34 CKD 3/4 with 12-week treatment [126]. In another
trial, rilonacept also reduced plasma hsCRP and IL-6 in patients with CKD G3-G4
(NCT00897715). Anakinra also reduce hsCRP in patients with hemodialysis (NCT00420290).
Taken together, IL-1β blockade demonstrated cardiovascular benefits in patients with
cardiovascular disease, which likely resulted from suppressing inflammation but not from
hyperglycemia control. The effect of IL-1β inhibition on the development of CKD is still
unknown.
Table 1.3: Current clinical trials of interleukin 1 blockade on diabetes
Trial Medicine Phase Patient Nr. Endpoint Treatment Effects
NCT00303394
[121]
Anakinra 2 T2D 72 Primary: HbA1c Treatment lower
NCT00942188
[127]
Anakinra 4 RA+T2D 41 Primary: ΔHbA1c Treatment higher
NCT00924105
[128]
CYT013-IL1bQb 1 T2D 48 Primary: adverse events NS
NCT01276106 AC-201 2 T2D 259 Primary: ΔHbA1c Treatment higher
NCT01298882
[122]













































1 T2D 98 Primary: ΔHbA1c Treatment lower
NCT01066715 Gevokizumab
(XOMA 052)
2 T2D 421 Primary: ΔHbA1c NS
NCT00942188
[123]
LY2189102 2 T2D 106 Primary: ΔHbA1c NS
T2D, type 2 diabetes. RA, rheumatoid arthritis. IGT, impaired glucose tolerance. AS, arthrosclerosis. MI,
myocardial infarction. hsCRP, high-sensitivity C-reaction protein. MACE, major cardiac adverse events. 3P-
MACE: cardiovascularmortality, myocardial infarction, stroke. 4p-MACE, 3p-MACE + hospitalization for unstable
angina. NS, not significant.
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Table 1.4: Current clinical trials of interleukin 1 blockade on kidney disease
Trial Medicine Phase Patient Nr. Endpoint Treatment Effects









NCT00897715 Rilonacept 2 CKD G3-G4 15 Primary: ΔhsCRP Primary: lower
NCT00420290 Anakinra N.A. CKD5 (HD), CHD 14 Primary: hsCRP Primary: lower
NCT03141983 Anakinra 2 CKD5(HD) 80 Primary.1: safety
Primary.2: ΔhsCRP
2021
CKD, chronic kidney disease. CHD, chronic heart disease. eGFR, estimated glomerular filtration rate. HD,
hemodialysis. CRP, C-reactive protein. hsCRP, high-sensitivity C-reaction protein. N.A., not applicable.
2 Hypothesis
CKD is a heterogeneous group of disorders and recognized as a global public health priority.
DM is a systemic disorder and a common cause for CKD. DKD implicates both systemic and
local sterile inflammation, which drives kidney structural and functional deterioration. Sterile
inflammation is secondary to DAMPs released from damaged cells and dying cells upon
diabetes-associated stimuli activating PRRs and subsequently inflammasomes, leading to the
activation of cytokines, chemokines, and adhesion molecules. Some diabetes-related triggers,
such as hyperglycaemia and mitochondrial ROS, activate NLRP3-dependent inflammasome
and lead to IL-1β maturation and release. IL-1β activates cells expressing IL-1R and induces a
board range of proinflammatory mediators. Given the central role of IL-1β in orchestrating
inflammation as well as the observation that an up-regulation of IL-1β in diabetic conditions,
IL-1 or IL-1R inhibition has been proven protective in vitro under diabetes-related conditions
and pre-clinical models of early stage of DKD. However, the hypothesis that IL-1β would drive
advance DKD has not been tested.
Meanwhile, an animal model with overt DKD is needed for preclinical study.
Uninephrectomy is a common tool to accelerate kidney impairment. Its main shortcoming is
surgery-related complications, such as lethality and kidney infection. Thus, a non-surgical
method which can reduce the number of functional nephrons in db/db mice would be
desirable. Besides, a non-surgical method is more in accord with 3R of animal welfare
(replace, reduce, and refine). Given oxalate-rich diet is a convenient method to generate
progressive nephrocalcinosis, tubular atrophy, and CKD in C56BL6 mice, we want to explore
the possibility of using oxalate-rich diet as a substitutive and non-surgical approach to
accelerate kidney impairment in db/db.
Thus, we hypothesize that:
1. An oxalate-rich diet could induce crystal deposition and GFR loss in db/dbmice.
2. IL-1β blockade by a specific anti-IL-1β IgG would have renoprotective effects in a mouse
model of DKD.
Accordingly, the aims of my study include:
1. We would replace uninephrectomy by a non-surgical approach of feeding oxalate-rich
diet to induce progressive CKD via triggering nephrocalcinosis and tubular atrophy.
2. We would investigate the therapeutic effects of IL-1β inhibition with anti-IL-1β antibody





Isofluran CP CP-Pharma, Burgdorf, Germany
Medetomidine Sanofi-Aventis GmbH, Paris, France
Midazolam Ratiopharm GmbH, Ulm, Germany
Mentanyl Zoetis GmbH, Germany
Atipamezol CP-Pharma, Burgdorf, Germany
Flumazenil Hexal AG, Munich, Germany
Buprenorphine Bayer Vital, Leverkusen, Germany
Animal surgery
BD Microlance™ Stainless Steel Needles Becton Dickinson, NJ, USA
BD Plastipak™ Syringes Becton Dickinson, NJ, USA
Sterile gauze balls (Mulltupfer) Verbandmittel Danz, Germany
Sterile swab Verbandmittel Danz, Germany
ETHIBOND EXCEL Polyester Suture 5-0 Ethicon, Germany
Vicryl™ 5-0 absorbable suture Ethicon, Germany
Bepanthen Eye and Nose Ointment Bayer, Germany
Surgical scissors and forceps Integra LifeSciences, France
Brinsea Octagon 20 Eco Incubator Auto Brinsea, UK
Infrared 100W Heat Emitting Bulb Healthcare Philips, Germany
Operation table Medax, Germany
Animal sample preservation
Histology embedding cassettes NeoLab, Germany
Formalin 4% Merck, Darmstadt, Germany
EDTA Carl Roth, Germany
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Animal diet










Vitamin A 25000 U/kg
Vitamin D3 1500 U/kg
Vitamin E 125 mg/kg
Iron (II) sulphate monohydrate 100 mg/kg
Zinc sulfate monohydrate 50 mg/kg
Manganese (II) sulphate monohydrate 30 mg/kg
Copper (II) sulfate pentahydrate 5 mg/kg
Sodium selenite 0.1 mg/kg
Calcium iodate Anhydrate 2.0 mg/kg
Oxalate-rich and control diet
Ingredients Quantity Control food Oxalate-rich food
Crude protein 17.7% + +
Crude fat 6.1% + +
Crude fiber 4.0% + +
Raw ash 2.4% + +
Strength 31.1% + +
Sugar 33.8% + +
Calcium 0.4% + +
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Vitamin A 19800 U/kg + +
Vitamin D3 2200 U/kg + +
Vitamin E 120 mg/kg + +
Vitamin K3 45 mg/kg + +
Vitamin C 350 mg/kg + +
Copper 8 mg/kg + +
Sodium oxalate 50 mmol/kg - +
3.2 Glomerular filtration rate measurement
NIC-Kidney device Medibeacon, Germany
Double-sided adhesive patch Lohmann, Neuwied, Germany
FITC-sinistrin Medibeacon, Germany
Rechargeable miniaturized battery Medibeacon, Germany
Sterile compress Verbandmittel Danz, Germany
Medical adhesive tape BSN Medical GmbH, Germany
Razor blades Gillette, USA
3.3 Urine and blood measurement
Mouse Albumin ELISA Quantitation Set Bethyl Laboratories, TX, USA
Creatinine FS Diasys, Holzheim, Germany
Urea FS DiaSys, Holzheim, Germany
God FS DiaSys, Holzheim, Germany
96 well MicroWell™ MaxiSorp™ plate Thermo Fisher, MA, USA
Nunc™ MicroWell™ 96-Well Microplates Thermo Fisher, MA, USA
Bovine serum albumin fraction v Roche, Mannheim, Germany
Tris Carl Roth, Karlsruhe, Germany
Sodium chloride Merck, Darmstadt,Germany
Tween 20 Sigma-Aldrich, Munich, Germany
Sodium carbonate Merck, Darmstadt, Germany
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Sodium bicarbonate Merck, Darmstadt, Germany
TMB Substrate Reagent Set BD Biosciences, NJ, USE
Sulfuric acid Sigma-Aldrich, Munich, Germany
pH meter WTW, Weilheim, Deutschland
Tecan GENios™ Microplate Reader Tecan, Germany
3.4 RNA isolation, cDNA conversion, real-time qPCR
RNA isolation
2-Mercaptoethanol Sigma-Aldrich, Munich, Germany
DNase and RNase free water Thermo Fisher, MA, USA
96% Ethanol Merck, Darmstadt,Germany
RNase AWAY® spray Sigma-Aldrich, Munich, Germany
RNAlater™ Stabilization Solution Ambion, MA, USA
PureLink™ RNA Mini Kit Ambion, Darmstadt, Germany
RNase-Free DNase Set Qiagen, Hilden, Germany
Homogenizer Ultra-Turrax® T25 IKA GmbH, Staufen, Germany
cDNA conversion
NanoDrop™ Spectrophotometer Biotechnologie, Erlangen, Germany
5x First Strand-Puffer Invitrogen, Karlsruhe, Germany
Acrylamid Ambion, Darmstadt, Germany
Dithiothreitol Invitrogen, Karlsruhe, Germany
dNTP Set GE Healthcare, Munich, Germany
Hexanucleotid-Mix Roche, Mannheim, Germany
RNAsin Promega, Mannheim, Germany
SuperScript II Reverse Transcriptase Invitrogen, Karlsruhe, Germany
Thermomixer 5436 Eppendorf, Hamburg, Germany
Real-time qPCR
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SYBR green I Sigma-Aldrich, Munich, Germany
PCR Optimizer Biomol, Hamburg, Germany
MgCl2 25mM Thermo Fisher, MA, USA
Bovine Serum Albumin PCR grade Thermo Fisher, MA, USA
PCR-Primer Metabion, Martinsried,Germany
Taq-Polymerase New England BioLabs, Ipswich, USA
10X Taq Buffer New England BioLabs, Ipswich, USA
Lightcycler 480 PCR plate with 96 wells Sarstedt, Germany
Optical lid strip for 96-well plates Sarstedt, Germany
LightCycler 480 Multiwell-Plate 96 Roche, Mannheim, Germany
LightCycler 480 Instrument Roche, Mannheim, Germany
3.5 Antibodies and reagents used in histology
Antibodies used in histology
Rat anti-mouse Mac-2 Cedarlane, ON, Canada
Anti-mouse Wilms Tumor (WT)-1 Cell signaling, Danvers, MA, USA
Anti-mouse Wilms Tumor (WT)-1 Santa Cruz Biotechnology, CA, USA
Guinea pig anti-mouse nephrin Acris Antibodies, Herford, Germany
Rabbit anti-mouse alpha smooth muscle actin Dako, Glostrup, Denmark
HRP-conjugated Anti-Goat secondary Ab Dianova, Hamburg, Germany
HRP-conjugated Anti-Rabbit secondary Ab Cell signaling, USA
Rabbit anti-human NLRP3 (ABF23) Merck, Darmstadt, Germany
Mouse anti-human CD68 (PG-M1) Dako, Glostrup, Denmark
Mouse anti-human IL1-alpha (LS-B1581) LifeSpan, Seattle, Washington, USA
Rabbit anti-human IL1-beta (ab82558) Abcam, Cambridge, UK
Reagents used in histology
Xylene Merck, Germany
Hydrogen peroxide Merck, Germany
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Paraffin Merck, Germany
Formaldehyde Merck, Germany
Fixation solution Acquascience, Uckfield, UK
DAB substrate chromogen system Dako, Glostrup, Denmark
Avidin-Biotin Complex Kits Vector Laboratories, CA, USA
Antigen unmasking solution Vector Laboratories, CA, USA
Avidin Vector Laboratories, CA, USA
Biotin Vector Laboratories, CA, USA
DAB Peroxidase Substrate Kit Vector Laboratories, CA, USA
Nuclear Fast Red solution Sigma-Aldrich, Munich, Germany
Antifade Mounting Medium with DAPI Vector Laboratories, CA, USA
Picro-sirius red solution Sigma-Aldrich, Munich, Germany
Periodic acid Carl Roth, Germany
Schiff Reagent Sigma-Aldrich, Munich, Germany
Nitric acid Merck, Germany
Silver nitrate Carl Roth, Germany
3.6 Miscellaneous
Falcon, 15/50 ml Greiner BioOne, Germany
Reaction tubes, 1.5/2.0 ml Paul Boettger, Germany
Safe lock tubes, 1.5/2.0 ml (PCR) Eppendorf, Germany
Cryovial, 2.0 ml Alpha Laboratories, UK
Refill pipette tips Greiner Bio-One, Germany
Serological Pipette, 5/10/25/50 ml Greiner Bio-One, Germany
EpT.I.P.S. refill pipette tips(PCR) Eppendorf, Germany
PBS PAN-Biotech, Germany
Tissue culture dish, 100 mm TPP, Trasadingen, Switzerland
Analytic Balance
BP 110 S Sartorius, Göttingen,
Germany
Mettler PJ 3000 Mettler-Toledo Greifensee, Switzerland
Heraeus, Minifuge T VWR, Darmstadt, Germany
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Heraeus, Biofuge primo Kendro Laboratory, Germany
Heraeus, Sepatech Biofuge A
Heraeus Sepatech, Munich,
Germany




Microtome HM 340E Microm, Heidelberg, Germany
Thermomixer 5436 Eppendorf, Hamburg, Germany
Vortex Genie 2™ Bender Hobein, Zurich, Switzerland
Water bath HI 1210
Leica Microsystems, Bensheim,
Germany
Easypet® pipette controller Eppendorf, Germany
Pipetman® pipette Gilson, Middleton, WI, USA
Research Pro electronic pipettor Eppendorf, Germany




All experiments were conducted according to the European equivalent of the NIH’s Guide for
the Care and Use of Laboratory Animals, i.e. EU directive 2010/63/EU, and received the official
permission from local government authorities (Regierung von Oberbayern, reference number:
55.2-1-54-2532-15-2014 and 55.2-1-54-2532-15-2017).
4.1.2 Experimental animals
Five- to six-week-old male C57BL/Ks (BKS) diabetic (BKS.Cg-m+/+Leprᵈᵇ/BomTac, genotype:
sp/sp) and non-diabetic wildtype mice (BKS.Cg-m+/+Leprᵈᵇ/BomTac, genotype: wt/wt) were
purchased from Taconic Biosciences (Lille Skensved, Denmark). Body weight upon arrival was
34.17 ± 2.31 g for diabetic mice, and 20.94 ± 1.31 g for non-diabetic mice.
4.1.3 Housing and husbandry
Mice were housed under standard conditions in a specific pathogen free facility. The facility
was equipped with a light system which had a 12 hours-12 hours light/dark cycle. The facility
was air-conditioned with target room temperature of 22 ± 4 °C and for relative humidity of 50-
70%. Mice were housed in groups of 2-3 in conventional filter top cages. Mice had ad libitum
access to autoclaved water and autoclaved standard chow diet or specific chow diet (all from
Ssniff, Germany); additional foodwas placed on the floor of cages for easy access. Extra nesting
material and wooden sticks for gnawing were provided for the whole study. Transparent red
plastic houses were also provided as enrichment except during surgery wound healing. Extra
bedding was provided every time and changed 3 times a week. All the bedding, enrichment,
cages, water, and food were sterilized before use.
4.1.4 Food and water consumption
Food and water consumption were monitor over one or two days for each measurement.
Overall consumption of one cage was calculated by the weight difference between the
starting and ending point. The consumption of one mouse was further calculated by dividing
the overall consumption of one cage by the total number of mice in each cage. Only mice
belonging to the same group were housed in the same cage.
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4.1.5 Glomerular filtration rate
GFR was determined by measuring the clearance of exogenous fluorescein isothiocyanate
(FITC)-conjugated sinistrin (Mannheim Pharma and Diagnostics) in conscious mice, a method
first describe by Schreiber A, et al. [132]. The dynamic change of FITC-sinitrin was recorded
by a miniaturized device attached to nude mouse skin. Plasma half-life of FITC-sinistrin was
then calculated by analyzing the continuous signal change of FITC-sinistrin captured by the
chip. We performed the measurement with minor in-house modifications [82]. In brief:
1. Mice were anesthetized with isoflurane. Fur around neck was moisturize with ethanol
and carefully shaved to expose skin of around 1.5 × 1.5 cm² while avoiding scratching.
2. A miniaturized FITC-sinistrin recording device was connected with a small battery and
attached onto the shaved skin via adhesive tapes.
3. Prior to FITC-sinistrin injection, leave the devices recording background signal for 15min.
4. Mice received intravenous injection of 150 mg/kg FITC-sinistrin.
5. Each mouse was conscious, kept individually in a filter top polypropylene cage without
food and water supply, and free to move around. The FITC-sinistrin signal was recorded
for 1.5-2.0 hours.
6. Devices were removed and analyzed by MPD Lab software.
A typical FITC-sinistrin signal curve consists three parts: the background signal recording
stage (before sinistrin injection), the peak stage (upon sinistrin injection), and decline stage. By
analyzing with MPD software, the value of plasma half-life of FITC-sinistrin (t½) was acquired








4.1.6 Sample collection and storage
Blood samples were collected after 4-hour fasting. Mice were anesthetized with 2.5-3.0 %
isoflurane and 2-3 L/h of oxygen flow. By puncture through facial vein using a micro glass
capillary, blood drops were collected into an EDTA-containing tube. For the blood collection
on the day of sacrifice, each tube contained 10 µl of 0.5 M EDTA for around 800 µl of blood
collection; for blood collection at each time point, each tube contained 7 µl of 0.5 M EDTA for
7-8 drops blood (around 100 µl). Tubes containing blood samples were then centrifuged at
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Figure 4.1: Animal study design for diabetic kidney disease by using db/dbmice fed with oxalate-rich food.
6000 rpm for 6 minutes. The upper plasma was transferred to another clean tube and stored
at -20 °C until further use.
Urine was collected through bladder massage. Urine was stored at -20 °C until further use.
Left kidney was taken and cut into 3 pieces. One piece (containing upper pole) was kept
in RNA-Later stabilization solution (Thermo Fisher, USA) and stored at -20 °C until further use.
One piece (middle parts) was preserved in 4% formalin for 24 hours and transferred to 70%
ethanol until paraffin block processing. Another piece (containing lower pole) was kept in liquid
nitrogen temporarily and further transferred to and stored at -80 °C.
4.1.7 Animal model: db/dbmice fed by oxalate-rich diet
Study design, allocation, study outcome, and group size
Fourteen-week-old male BKS diabetic (BKS.Cg-m+/+Leprᵈᵇ/BomTac, genotype: sp/sp) were
used. As shown in Figure 4.1, db/db mice were randomly distributed into two groups: fed
with control diet or with oxalate-rich diet at a ratio of 1 : 2.5 (n=10 for control diet, n=25 for
oxalate-rich diet). GFR and blood collection was done every 10 days. After 30 days, mice were
sacrificed. GFR was the primary endpoint. Group size calculation was based on GFR as a
primary endpoint. The group size was calculated based on previous studies [133, 134, 135].
4.1.8 Animal model of diabetic kidney disease: uninephrectomized db/db
Study design
To build up an experimental mouse model of diabetic kidney disease with more clinical
meaningfulness, a db/db model in BKS strain was utilized in combination with a morning
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Figure 4.2: Study design for testing anti-IL-1β in a mouse model of diabetic kidney disease
uninephrectomy, as a strategy to accelerate diabetic kidney disease progress. As shown in
Figure 4.2, at age 7 weeks db/db mice and wild type mice were randomly either received
uninephrectomy or sham surgery; thus mice were primarily divided into 4 groups: db/dbmice
with uninephrectomy (DM-1K), db/db mice with sham surgery (DM-2K), wild type mice with
uninephrectomy (WT-1K), and wild type mice with sham surgery (WT-2K). DM-1K group was
further allocated into two groups: at the age of 18 weeks, a time point when kidney
impairment in DM-1K mice was prominent, one group received control IgG (DM-1K+IgG
(DM-1K+IgG)), the other group received anti-IL-1β IgG (DM-1K+anti-IL-1β
(DM-1K+anti-IL-1β)). DM-1K+IgG and DM-1K+anti-IL-1β were intraperitoneally administrated
with antibody at 10 mg/kg weekly for a total of 8 weeks, while the other 3 groups remained
no treatment. WT-2K, WT-1K, and DM-2K here functioned as healthy control, control of
uninephrectomy, and control of db/db background, respectively. All mice were sacrificed at
age 26 weeks.
Group size and allocation
Base on GFR as a primary endpoint and data from previous studies, sample size was calculated
[133, 134, 135]. The group size for WT-2K, WT-1K, DM-2K, DM-1K+IgG, and DM-1K+anti-IL-
1β was 5, 5, 9, 8, and 9, respectively. Allocation within DM-1K was performed by matching
according to mouse data collected at age 17-18 weeks, including microalbuminuria, GFR, and
body weight.
Experimental outcomes
GFR was the primary endpoint. Albuminuria, histology, and gene transcription levels were
secondary endpoints.
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Uninephrectomy
1. Preoperative analgesia: mice were orally administrated with 2 drops Metamizol
(Novalgin) per 30 g mouse weight.
2. Narcosis: mice were intraperitoneally injected with 2.5 ml/kg body weight of narcosis
mixture (corresponding to midazolam 5 mg/kg, medetomidine 0.5 mg/kg, fentanyl 0.05
mg/kg) and then placed inside a 37 °C chamber device. Prior to the surgery, depth of
anesthesia (anesthesia stage III 2) was checked by the sign of missing pain reaction in the
inter-toe reflex.
3. Surgery:
(a) Mice were immobilized on a heating plate for heat supplying (device temperature
set at 40 °C).
(b) Eyes were applied with Bepanthen creme to protect from drying.
(c) Fur around the area of incision was moisturized with ethanol, shaved with a blade,
and sterilized with povidone-iodide.
(d) Skin and muscle layers were cut with scissor, thus peritoneal cavity was accessible.
Kidney (spleen-side) was pulled out of the peritoneal cavity with swabs and forceps.
Renal hilum was then exposed by removing the surrounding adipose tissue.
(e) A segment of 5-0 non-absorbable suture was placed around the hilum. A ligation
was made around the hilum. Kidney was excised. The stump with sutures was put
back into the peritoneal cavity.
(f) Peritoneal andmuscle layers were sutured with 5-0 absorbable suture (Vycril). Skin
was sutured with non-absorbable 5-0 suture (Ethibond).
4. Mice were subcutaneously injectedwith Buprenorphin 0.1mg/kg (=33.34ml/kg of 0.006
mg/ml solution) 30 minutes before antagonization.
5. Antagonization of narcosis: mice were subcutaneously injected with 8.5 ml/kg body
weight of antagonist-mix (containing 0.5 mg/kg of flumazenil and 2.5 mg/kg of
atipamezol), and then were accommodated in a 37 °C chamber device until waking up.
6. Post-surgery analgesia: mice were applied with s.c. 0.1 mg/kg (=33.34 ml/kg of 0.006
mg/ml solution) every 12 hours for three days.
Antibody preparation
Antibodies were kindly provided by Hoffmann-La Roche. The antibody is monoclonal antibody
and produced by engineered mouse hybridoma cells [136]. The antibody has specificity with
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human IL-1β, strong cross reactivity withmouse IL-1β, and no reactivity with IL-1α. All of above
was verified by protein-protein interaction assays based on ELISA.
4.2 Histology
As mentioned before, histology samples were first fixed in 4 % formalin for 24 hours and then
in 70 % ethanol. Subsequently, tissues were processed, preserved in paraffin blocks, sliced into
sections, deparaffinized, and rehydrated. The steps are as follows.
1. Processing: tissues were incubated in alcohol (70%, 96%, 100%) to remove the residual
water inside of tissues. Then tissues were treated with xylene to remove the residual
alcohol.
2. Embedding: tissues were embedded in lipophilic paraffin to remove xylene and became
solid. Until the paraffin blocks were cooled down, sections with certain thickness were
made by slicing the blocks with a microtome.
3. Deparaffinization: sliced sections were treated with xylene for 5 minutes for 2 times to
remove the paraffin.
4. Rehydration: sections were incubated in in alcohol with gradually decreased
concentration for two minutes each (100% for three times, 96% for two times, 70% for
one time) to regain hydration. Wash sections with PBS for 7 minutes.
Rehydrated sections were ready for non-immunostaining and immunostainings. For
immunostainings, the general procedurs are as follows:
1. Blocking endogenous peroxidase: sections were incubated in 30 % peroxidase for 20
minutes at room temperature in the dark and then washed with PBS for seven minutes.
2. Antigen unmasking: sections were incubated in boiled 10 mM sodium citrate buffer (pH
6.0), cooled down, then washed in PBS for 7 minutes.
3. Blocking avidin and biotin: sections were treated with avidin blocking solution for 15min
and then washed briefly in PBS. Sections were treated with biotin blocking solution for
15 min and then washed briefly in PBS.
4. Blocking non-specific binding: sections were treated with 10 % normal goat serum for
10 minutes at room temperature. Sections were ready for further primary antibody
incubation.
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5. Primary antibody incubation: sections were treated with primary antibody for one hours
at room temperature or 4 °C overnight and then washed in PBS for seven minutes.
6. Secondary antibody incubation: sections were treated with biotinylated secondary
antibody for 30 minutes in room temperature and then washed in PBS for seven
minutes.
7. Sections were treated with avidin–biotin complex solution for 30 minutes in room
temperature and then washed in PBS and Tris-HCl buffer.
8. Staining: sections were stained in staining solution containing 200 mL 37 °C Tris-HCl
buffer, 4 mL DAB solution, 1 mL NiCl and 500 µL 3 % peroxidase.
9. Sections were counter-stained with methyl green.
10. Sections were dehydrated by incubation with 96 % for 10 seconds, 100 % ethanol for 10
seconds, and xylene for 10 seconds. Then sections were mounted with cover lips.
Glomerular size measurement in PAS staining
The details for PAS staining are as follows:
1. After rehydration, sections were treated with 0.5 % periodic acid solution for 5 minutes
and then washed in distilled water for 5 minutes.
2. Sections were incubated in Schiff reagent for 5 minutes and then washed in 37 °C tap
water for 3 minutes. Repeat the washing step.
3. Sections were counter-stained with hematoxylin for 2 minutes and then washed in tap
water for 5 minutes.
4. Sections were dehydrated with 90% of ethanol and covered with a cover lip.
In PAS staining, images of at least 25 glomeruli were taken separately with microscope (at
400x magnification). Only glomeruli with a vascular pole or urinary pole were chosen.
Glomerular tuft and capsule were outlined and the area were quantified (µm²) with ImageJ
software, respectively. Tuft/capsule ratio was obtained by dividing the tuft area (µm²) by
Bowman’s capsule area (µm²) in percentage.
Mac-2 staining
Sections were stained by Mac-2 antibody to target macrophages (Rat anti-mouse Mac-2,
1:5000, Cederlane). For each section, around 15-20 glomeruli in cortex area and with a
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vascular pole or urinary pole were chosen. Glomerular Mac-2 positive cells were counted.
Results were reported as positive cells per glomerulus.
WT-1 staining
Sections were stained with anti-mouse Wilms Tumor-1 (WT-1) antibody by
immunohistochemistry method (1:200, Santa Cruz Biotechnology). For each section, 15-20
glomeruli in the cortex and with a vascular pole or urinary pole were chosen. WT-1 positive
cells at the junction between capsule and tufts were excluded. Results were reported as
positive cells per glomerulus.
WT-1/Nephrin staining
Sections were staining by immunofluorescence double staining with WT-1 antibody
(anti-mouse WT-1, 1:25, Cell signaling, MA, USA) and Nephrin antibody (guinea pig
anti-mouse nephrin, 1:100, Acris Antibodies, Herford, Germany). For each section, 15-20
glomeruli in the cortex were chosen. A typical positve cell showed robust WT-1 staining signal
overlapping with DAPI and surrounded by nephrin staining. Results were reported as positive
cells per glomerulus.
Alpha smooth muscle actin (αSMA) staining
Sections were staining with αSMA (rabbit anti-mouse αSMA, 1:500, Dako, Hamburg,
Germany). By using software Photoshop, a whole-section image was generated by merging
series of images taken under low magnitude microscopy. Merged images were then corrected
for background by software ImageJ. Area of medulla, especially those containing big blood
vessels, was excluded by software Photoshop. Cortex area was measured by software ImageJ
in µm² (Area-C). Positive area was measured by ImageJ in µm² (Area-αSMA). The percentage
of Area-C over Area-αSMA was reported as positive area/section, %.
Picro-sirius red staining
The staining procedures are as follows.
1. Sections were warmed in warm bath (56 °C for 1 hour or 37 °C overnight).
2. Sectionswerewashed by xylene for 5minutes twice, ethanol (100%, 95%, 70%, and 50%)
for 2 minutes twice, and distilled water for 2 minutes twice.
3. Sections were treated with adequate picro-sirius red solution and incubated at room
temperature for 60 minutes.
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4. Sectionswerewashed twicewith acidifiedwater. ThenWaterwas removed fromsections
by shaking.
5. Sections were dehydrated 100% Ethanol for 10 seconds. Repeat twice.
6. Sections were washed in xylene twice.
7. Sections were covered by mounting medium and cover slides.
Quantification was done by software ImageJ. First, glomeruli with urinary pole or vascular
pole were selected. Glomerular tuft area was measured in µm² (Area-G). Then picro-sirius red
area was selected andmeasured in µm² (Area-PG). The percentage of Area-G over Area-PGwas
reported as positive area/tuft area, %.
Pizzolato staining
A paraffin section of 6 µm was used. The steps are as follows.
1. Paraffin sections were deparaffinized and cover with distilled water.
2. Silver nitrate solution was prepared by mixing equal amounts of 5% silver nitrate and
30% hydrogen peroxide.
3. Sections were treated with sufficient silver nitrate solution so that tissues were totally
covered.
4. Sections were heated with a 60-watt bulb for one hour at a distance of 15 cm and then
rinsed thoroughly with distilled water twice.
5. Sections were counter-stained for 5 minutes in nuclear fast red solution and then rinsed
with distilled water.
6. Sections were dehydrated in 95% alcohol, then 100% alcohol, and in xylene, repeat twice
for each.
7. Sections were covered with mounting medium and cover slides.
4.3 Blood and urine measurement
Urine albumin ELISA
Urine albumin levels were measured by ELISA (Bethyl laboratories) following manufacturer’s
instructions. The procedures are as follows:
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1. Goat anti-mouse albumin coating antibodies were diluted in 100 µl 0.05M
carbonate-bicarbonate (pH 9.6) at a concentration of 10 µg/ml (100-fold dilution of
stock). Diluted antibodies were added to a 96-well plat-bottom plate (MaxiSorp,
Thermo Fisher) overnight in 4 °C and then washed for three times.
2. Plates were coated with 200 µl coating buffer which contained 1% bovine serum albumin
for at least 30 minutes at room temperature and then washed for 3 times.
3. Samples were diluted for 200-1000 times with ELISA diluent. Plates were coated with
100 µl sample dilution or standards for 1 hour at room temperature and then washed for
five times.
4. Plates were coated with 100 µl 10 ng/ml HRP conjugated goat anti-mouse albumin
detection antibody (100,000-fold dilution of stock) for one hour at room temperature
and then washed for five times.
5. Plates were coated with 100 µl tetramethyl benzidine substrate mix in the dark without
covering for around 5-10 minutes.
6. Plates were added with 100 µl of stop solution (2N sulfuric acid).
7. Plates were read by an ELISA reader for measuring the absorbance at 450 nm within 30
minutes.
8. A standard curve of concentration versus absorbance was created by sigmoidal four
parameter logistic curve fitting. The albumin concentration of each samples was
converted accordingly.
Urine creatinine
Urine creatinine was measured by Jaffe method (Creatinine FS, Diasys, Germany). Urine
dilution was prepared by mixing urine and water at 1:9 ratio. A total of 10 µl urine dilution
and standards were loaded to a 96-well plate-bottom plate. Reaction reagents were mixed
and loaded to the plate at 200 µl. Plates were read by an ELISA reader for measuring the
absorbance at 490 nm after 1 minute, 3 minutes, and 15 minutes (endpoint). In our study,
only the endpoint reading was used.
Blood urea nitrogen
Blood urea was measured by enzymatic method (Urea FS, Diasys, Germany). Urine (2 µl) and
standards were added to a 96-well plate-bottom plate. Reaction reagents were mixed and
added to the plate at 200 µl. Plates were read by an ELISA reader for the absorbance at 360
nm after 1 minute (T1), 3 minutes (T2), and 15 minutes (endpoint). In our study, only the
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kinetic reading (value difference between T1 and T2) was used for further calculation of urea
concentration. Urea nitrogen was converted by multiplying urea concentration by 0.467.
Glucose
Blood glucose was measured by enzymatic photometric method (”GOD-PAP”) (Glucose GOD
FS, DiaSys, Holzheim, Germany). Plasma (2 µl) and standards were loaded to a 96-well plate-
bottom plate. Reaction reagents were added to the plate at 200 µl. Plates were read by an
ELISA reader for the absorbance at 490 nm after 10 minutes.
4.4 RNA isolation, cDNA synthesis, real-time qPCR
RNA isolation
RNA was isolated according to manufacturer’s instruction with minor modifications. The steps
are as follows:
1. Lysis buffer containing 10% β-mercaptoethanol and 70% ethanl were prepared.
2. A small piece of kidney was cut and placed in a tube containing 600 µl 10%
β-mercaptoethanol lysis buffer.
3. The kidney piece was homogenized for 30-40 seconds for two times.
4. The homogenized produce was centrifuged for 6000 rpm, 5 minutes.
5. The supernatant of centrifugedhomogenized productwasmixedwith 500µl 70%ethanol
and transferred into the isolation column.
6. The tube was centrifuged at 11000 rpm for 30 seconds.
7. A volume of 350 µl of wash buffer I was added to the isolation column.
8. RNase-Free DNase was prepared in RNase-Free Buffer. Eighty µl of RNase-Free DNase
was added to each isolation column and incubated at room temperature for 15 minutes.
9. A volume of 350 µl of wash buffer I was added to columns.
10. Columns were centrifuged at 11000 rpm for 30 seconds.
11. The isolation columns were transferred to a new collection tube.
12. Five hundred µl of Wash buffer II into isolation columns and centrifuged at 11000 rpm
for 30 seconds. Repeat once.
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13. After the waste in the collection tubes was discarded, the columns were centrifuged at
11000 rpm for 1 minute.
14. Isolation columns were transferred to new collection tubes.
15. Thirty-five µl of RNase free water was added to the columns and incubated at room
temperature for 1 minute. Tubes were centrifuged at 11000 rpm for 1 min
16. RNA concentration and its purity were measured by Nanodrop. Only samples with
A260/280 at 1.95-2.10 and A260/230 at 1.90-2.30 were proceeded to further
measurement. Samples were stored at -80 °C.
cDNA synthesis
The detailed procedures of RNA conversion is listed as follows:
1. For a reaction size of 22.45 µl, RNA was diluted to a concentration of 66.67 ng/µl in 15
µl and added to RNase-free tube.
2. Master mix was prepared (for one sample) by mixing 4.5 µl 5x buffer, 1.0 µl DTT, 0.45
µl dNTPs, 0.5 µl Rnasin, 0.25 µl acrylamide, 0.25 µl Hexa, and 0.5 µl superscript reverse
transcriptase and added to diluted RNA.
3. Another master mix in which the superscript reverse transcriptase was replaced by
RNase-free water in the same volume was added to diluted RNA as a
no-reverse-transcriptase control (RT-).
4. Mixed samples were incubated at 42 °C for 1.5 hour on a thermal shaker for reaction and
90 °C for 5 min to terminate the reaction.
5. Samples were stored at -20 °C until further use.
Real-time quantative polymerase chain reaction
Real-time quantative polymerase chain reaction (RT-qPCR) was performed by SYBR Green
method in a reaction size of 20 µl. The detailed procedures were as follows:
1. cDNA reaction was diluted 10 times with nuclease-free water and added to a 96-well
Lightcycler plate at 2 µl.
2. A master mix was prepared as follows (for one sample): 0.6 µl 10 µM forward primer,
0.6 µl 10 µM reverse primer, 10 µl 2x SYBR green I dye, 0.16 µl Taq DNA polymerase, and
6.64 µl nuclease-free free water. Eighteen µl of master mix were added to the 96-well
Lightcycler plate.
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3. Plates were sealed and shortly centrifuge to spin down reagents on the wall.
4. We used LightCycler 480 to perform DNA amplification.
(a) Pre-incubation: the target temperature was 95 °C and held for 5 minutes. This step
allows to denaturize cDNA and activate the Taq DNA polymerase.
(b) Amplification: amplification was set at 40 cycles. For each cycle, it consists of 15
seconds of annealing at 60 °C and 40 seconds of extension at 72 °C.
(c) Melting curve. First target temperature target was set at 95 °C and held for 5
seconds. Second target was 65 °C and allowed continuous decreased heating over
95 °C-65 °C.
Reference genes (18S rRNA) was carried out under same conditions and same reaction
components. No template controls for target and reference genes were also carried out by
replacing diluted cDNA by water in the same volume. When the target gene was chemokine
or cytokine, cDNA derived from spleen tissues was added as a positive control. Cycle
threshold (CT) values for 18s rRNA (CT𝑟𝑒𝑓) and target gene (CT𝑡𝑎𝑟𝑔𝑒𝑡) were measured by
LightCycler 480. Relative mRNA/18s rRNA equals to 2𝐶𝑡𝑡𝑎𝑟𝑔𝑒𝑡−𝐶𝑡𝑟𝑒𝑓. Results were presented
as relative mRNA/18s rRNA in log₁₀.
Primers
Primers for RT-qPCR were designed by the primer designing tool at NCBI or obtained from
published literature or online primer banks. The amplicon size was targeted at 70-150 bp. The
primer specificity was checked by primer-BLAST at NCBI before synthesis. All primers were
synthesized by a commercial company (Metabion, Germany) at a concentration of 100 µM.
Primers were diluted to 10 µM in ultra-pure water. The primer specificity was tested prior to
experiment by using cDNA samples derived from tissues expressing target genes (kidney or
spleen) to exclude primer-dimer or non-specific products. The sequence of primers used in
our study are shown in Table 4.1.
4.5 Human kidney biopsy transcriptomics
The transcriptomics project was under the framework of the European Renal cDNA Bank and
approved by local ethical authorities [137, 138, 139]. Kidney biopsy samples were taken from
7 patients with DKD and 18 healthy individuals (living kidney donors) with informed consent
[136]. The preservation, isolation, and reverse transcription for kidney RNA samples were
described previously [137]. Briefly, Kidney tissues were preserved in RNase inhibition
condition at -20 °C (RNAlater, Ambion, USA). Under a stereomicroscope, tissue sections were
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cut into glomerular and tubulointerstitial parts. Then total RNA from each compartments was
lysed in guanidine thiocyanate, isolated with silica-gel column, and underwent reverse
transcription [137]. The microarray was performed on Affymetrix HG-U133 Plus 2.0
microarrays system following the instruction from manufacturer. An initial data processing
such as background correction and normalization was performed by robust multichip analysis
method [138, 139, 136]. Gene annotation was analyzed with Human Entrez Gene custom CDF
annotation version 18 [136]. Significantly expressed genes were identified with significance
analysis of microarrays [140, 139]. A q-value ≤ 5% was considered significant.
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4.6 Immunohistochemistry of human kidney biopsies
The details for immunohistochemistry was described previously [136]. Kidney biopsies were
from the sample library at the Service of Pathology, University Hospital Geneva. The project
was approved by local ethical committee (CEREH number 03-081). Tissues were obtained
from eight diabetic patients and one healthy control with informed consent. Of the eight
diabetic patients, all developed proteinuria; 2 were female and 6 were male; 2 were T1D and
6 were T2D. The tissue for healthy control was a tumor-free part from a patient who was
diagnosed with neoplasia and underwent nephrectomy. Tissues were preserved in paraffin
blocks and cut into 3 µm serial sections. The deparaffinization and antigen retrieval procedure
were performed in a standard manner. Serial sections were treated with following four
primary antibodies: 1. rabbit anti-human NLRP3 (1:1500), 2. mouse anti-human IL-1α (1:500),
3. rabbit anti-human IL-1β (1:400), 4. mouse anti-human CD68 (1:100). Sections were
incubated with above antibodies for 1 hour at room temperature, incubated with second
antibodies for 30 minutes at room temperature. Then sections were stained with DAB and
counter-stained by Mayer’s hematoxylin. We also perform negative controls which were
performed in the same condition except omitting the primary antibodies.
4.7 Statistical analysis
Data fromdropoutswere included in analysis. Data are presented asmean ± standard deviation
(SD). A p value ≤ 0.05 was considered statistically significant. Comparison between two groups
was performed sequentially by normality test, homoscedasticity test (equality of variance), and
comparison test as shown in Table 4.2. Comparison between more two groups was performed
sequentially by normality test, homoscedasticity test (equality of variance), comparison test,
and post hoc analysis as shown in Table 4.2. Statistical analysis and data visualization were
performed with R studio or Graphpad Prism.
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Table 4.2: Statistical methods for comparing the means between two or multiple groups
Normality Homoscedasticity Comparison Test Post-hoc-test Note
Comparison between two groups
Shapiro-Wilk test Levene’s test
Student’s t-test n.a.
P>0.05 for Shapiro-Wilk test
and P>0.05 for Levene’s test
Welch’s t-test n.a.
P>0.05 for Shapiro-Wilk test
and P<0.05 for Levene’s test
Wilcoxon rank-sum
test
n.a. P<0.05 for Shapiro-Wilk test
Comparison between multiple groups
Shapiro-Wilk test Levene’s test
One-way ANOVA test
Tukey
P>0.05 for Shapiro-Wilk test
and P>0.05 for Levene’s
test, comparing the mean
to every other group’s mean
Dunnett
P>0.05 for Shapiro-Wilk test
and P>0.05 for Levene’s test,
comparing the mean to a
specific group’s mean
Kruskal–Wallis test Dunn
P<0.05 for Shapiro-Wilk test
or P<0.05 for Levene’s test
n.a., not applicable
5 Results
5.1 Part I. db/dbmice fed by oxalate-rich food
In order to see, whether we could replace surgical kidney mass reduction by an oxalate-rich
diet to cause GFR decline and progressive nephrocalcinosis also in db/db mice, mice received
oxalate-rich diet, GFR was measured periodically, and kidney histology was analysed after
30-day feeding. GFR was indistinguishable between control and oxalate diet during 30 days of
observation (Figure 5.2E). Oxalate-rich diet did not induce massive crystal deposition in
kidney as known from C57BL/6N mice (Figure 5.2A-B). Mortality between these two diets was
similar (Figure 5.2A). There was no difference in water intake (Figure 5.2B). Oxalate diet group
consumed less food at day 10 and day 30 (Figure 5.2C). Body weight was similar between
oxalate-rich diet and controls (Figure 5.2D). Thus, oxalate-rich diet did not induce GFR decline
and nephrocalcinosis in db/dbmice.
Figure 5.1: Oxalate-rich diet did not induce massive crystal deposition in mouse kidney. A, Pizzolato staining for
oxalate crystals. After 30-day feeding, mouse kidney sections were stained with pizzolato staining. Magnification
100x. B, Quantification of pizzolato staining. Crystal deposition was quantified and presented as percentages of
positive area over total kidney area. N=8 in control diet group, n=12 in oxalate-rich diet group. ***p <0.001.
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Figure 5.2: Effects of oxalate-rich diet ondb/dbmice. A, Kaplan-Meier survival curves. The survivalwas compared
by a standard rank test betweenmice fed with regular food (black) and oxalate-rich food (yellow). N=10 in regular
food, n=25 in oxalate food. B, Water intake. C, Food intake. Water and food intake were measured by recording
the consumption over 24 hours from each cage. Each cage housed 2-3 mice from the same group. Each value in
the figure represented the average consumption of each cage. **p <0.01, ****p <0.0001. D, Body weight. E, GFR.
GFR was measured every 10 days. GFR, glomerular filtration rate.
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5.2 Part II. Interleukin-1β blockade in diabetic kidney disease
5.2.1 Interleukin-1β expression in diabetic kidney disease
Interleukin-1β gene expression in patients with diabetic kidney disease
First, in order to see whether IL-1 pathway is activated inside the kidney in the clinical
scenario of diabetes, gene expression levels of IL-1α/β, their receptors, and NLPR3 were
analyzed in human kidney biopsies from DKD patients and living donors by micro-dissected
microarray. Kidney biopsies were collected from 7 patients with DKD, and from 18 living
donors served as healthy controls. Result was shown in Figure 5.3. Glomerular and
tubulointerstitial IL1B expression levels in DKD patients were 1.808 times and 1.273 times
higher than those in living donors, respectively. IL1R1 expression in glomeruli and
tubulointerstitium from DKD patients were 1.226 times and 1.302 times higher, respectively,
compared with living donors. DKD patients also expressed a higher level of NLRP3 in
glomeruli, which was 1.274 times of that in living donors. IL1A expression level was too low to
detect. IL1R2 expression levels, either in glomeruli or in tubulointerstitium, was similar
between DKD patients and living donors. Together, kidney gene expression of IL-1β, IL-1R1,
and NLRP3 are increased in human DKD.
Figure 5.3: IL-1β gene expression in human kidney. Kidney biopsies were obtained from 7 DKD patients with or
from living donors, micro-dissected into glomerular and interstitial compartments, and further proceeded to RNA
microarray analysis. Gene expression levels of each compartment in diabetic kidneys were normalized to those
in healthy kidneys and presented as average fold changes in the heat map. BC, below cut-off; NS, not significant.
DKD, diabetic kidney disease.
5.2. PART II. INTERLEUKIN-1Β BLOCKADE IN DIABETIC KIDNEY DISEASE 49
Interleukin-1β protein expression in patients with diabetic kidney disease
To further confirm if IL-1β pathway is induced in DKD, protein expression levels of IL-1β, IL-1α,
and NLRP3 were tested by immunohistochemistry in human kidney biopsies.
First, a total of 8 biopsies were collected, which were from patients diagnosed with DKD
and varying severity of interstitial fibrosis and tubular atrophy (IFTA), including 1 case with 0%
IFTA, 1 with 15 % IFTA, 2 with 30% IFTA, 1 with 50% IFTA, 2 with 60% IFTA, and 1 with 70 % IFTA.
Then the specificity of antibodies for immunohistochemical staining was tested. As shown in
Figure 5.4, compared with negative control omitting primary antibodies, staining with each
antibody showed clear and specific signals.
Biopsy tissues were stained for CD68, IL-1α, IL-1β, and NLRP3, and the representative
figures from 0% IFTA and 70% IFTA was shown in Figure 5.5 A. Here CD68 staining was
performed additionally to see if macrophages are the cell origin of IL-1α, IL-1β, and NLRP3.
The biopsy with 70% IFTA showed stronger CD68, IL-1α and IL-1β staining than biopsy with 0%
IFTA. The NLRP3 staining was similar between 0% IFTA and 70% IFTA.
Further, a semi-score (0-3) was made to quantify the staining intensity in each biopsy in 5
compartments, including: glomerular tuft, Bowman’s capsule, distal tubule, proximal tubule,
and interstitium. Results were shown in 5.5B. Biopsies with higher IFTA score tended to have
higher scores of CD68 staining. This tendency was also true in IL-1α and IL-1β, but not in NLRP3
staining. Of note, staining pattern of IL-1α was diffuse while that of IL-1β was more condensed
andmainly located in some cells scattered in glomeruli tufts and tubulointerstitium, suggesting
that IL-1β might originate from macrophages. IL-1β staining was also found in some tubular
cells but to a lesser extent.
Figure 5.4: Specificity of IL-1α, IL-1β, and NLRP3 staining in human kidney biopsies. For IL-1α and IL-1β staining,
kidney tissue was obtained from a patient with diabetic kidney disease and with 60% IFTA; for NLRP3 staining,
kidney tissue was obtained from a patient with DKD and 40% IFTA. Upper: negative control; primary antibody was
omitted. Lower: primary antibodies were added. Original magnification 320x in IL-1α and IL-1β staining, and 250x
in NLRP3 staining. IFTA, interstitial fibrosis and tubular atrophy.
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Linear regressions of IFTA score and the sum of score from each staining was made as
shown in Figure 5.5C. Score of CD68 (R=0.82, p=0.012) and score of IL-1β (R=0.73, p=0.042)
was significantly correlated with IFTA.
Thus, IL-1β protein expression is increased in human DKD. IL-1β mainly derives from
infiltrating immune cells in glomeruli and interstitium and also from few tubular epithelial
cells.
Figure 5.5: IL-1α, IL-1β, and NLRP3 protein expression in human kidney biopsies. A, Immunohistochemistry
staining. Kidney biopsy tissues were stained for CD68, IL-1α, IL-1β, and NLRP3. Representative images were from
biopsies scored with IFTA 0% and IFTA 70%, respectively. Original magnification 320x in IFTA 0% and 200x in IFTA
70%. B, Semi-quantification for immunohistochemistry staining. Staining results were semi-quantified by scoring
0-3 points for five kidney compartments: glomerular tuft, Bowman’s capsule, distal tubule, proximal tubule, and
interstitium. Zero point represents for no positive staining, 3 for very strong staining. Base on the scores, stacked
bar charts were generated. NA, not applicable. C, Linear regression of IFTA and score of staining. The correlation
of the sum of staining scores from all five kidney compartments and IFTA was analyzed by linear regression. N=1
in 0%; n=1 in 15%; n=2 in 30%; n=1 in 50%; n=2 in 60%; n=1 in 70%. IFTA, interstitial fibrosis and tubular atrophy.
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Interleukin-1β expression in diabetic mice
Next, in order to see, if our animal model of DKD also has the feature of increased IL-1β
expression in kidney, we analyzed transcription levels of IL-1β in kidneys from db/db mice by
RT-qPCR. We analyzed kidney gene expression in 26-week-old db/db mice that had
uninephrectomy at age 8 weeks (DM-1K). Age controlled db/db mice with sham surgery
(DM-2K), age controlled wild type mice with a morning uninephrectomy at the age of 8 weeks
(WT-1K), as well as age controlled wild type mice with sham surgery (WT-2K) served as
controls.
As shown in Figure 5.6, expression level of IL1b in DM-1K was higher than that in DM-2K
group and reached a statistical significance. A significant higher level of Il1r1 expression was
also shown in DM-2K when comparing toWT-2K. Expression levels of Il1a, Il1r2 andNlrp3were
similar between each group. Together, IL-1β gene expression is increased in db/db mice with
uninephrectomy.
Figure 5.6: Kidney IL-1β expression in db/db mice. Kidneys RNA from 26-week-old wild type mice and db/db
mice with or without uninephrectomy were isolated and measured for Il1a, Il1b, Il1r1, Il1r2, and Nlrp3 expression
levels by real-time quantitative PCR. Data were presented as log10 transformation of relative gene expression to
18S rRNA. N.S., statistically not significant; *p <0.05.
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5.2.2 Effects of interleukin-1β blockade on metabolic parameters
In order to see if IL-1β blockade has an effect on DKD, 18-week-old DM-1K mice were
intraperitoneally administrated with anti-IL-1β IgG antibody or control IgG for 8 weeks. First,
effects of IL-1β blockade on metabolic parameters were analyzed to see if treatment
influenced obesity and hyperglycemia.
Body weight was monitored every week. Before the treatment, db/db mice with
uninephrectomy (Unx) (DM-1K) had a lower body weight than their sham surgery controls
(Figure 5.7 A). Mice receiving anti-IL-1β IgG had similar body weight compared to those
received IgG treatment (5.7 B).
Food and water intake were also monitored periodically after treatment initiation. Mice
with anti-IL-1β IgG treatment had similar food and water consumption compared to mice in
IgG controls (Figure 5.7 C-D).
Fasting blood glucose levels was also measured periodically after treatment initiation.
Compared with sham surgery group, db/db mice with uninephrectomy had similar fasting
blood glucose levels, indicating uninephrectomy did not affect glucose metabolism.
Compared with mice receiving control IgG, mice receiving anti-IL-1β IgG had similar fasting
glucose levels during the 8-week treatment period (Figure 5.7 E).
Taken together, anti-IL-1β IgG treatment has no effects on body weight, food or water
consumption, or fasting blood glucose in uninephrectomized db/dbmice.
5.2. PART II. INTERLEUKIN-1Β BLOCKADE IN DIABETIC KIDNEY DISEASE 53
Figure 5.7: Body weight, food consumption and water intake, fasting blood glucose. A, Body weight before the
initiation of treatment. Body weight was recorded every week until treatment started. ****p <0.0001 in two-way
ANOVA test. B, Body weight after treatment started. After anti-IL-1β IgG or control IgG treatment initiated, body
weight was recorded until the end of treatment. N.S. represents for not significant in the two-way ANOVA test.
C, Water intake. D, Food intake. Water and food intake were measured by recording the consumption over 24
hours. N.S., not significant in the two-way ANOVA test. E, Fasting blood glucose. Mice were fasted for 4 hours and
plasma was collected. Glucose was tested by enzymatic photometric method.
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5.2.3 Effects of interleukin-1β blockade on kidney function
Next, GFR was tested periodically to see if anti-IL-1β IgG has an effect on kidney function in
diabetic mice.
GFR was measured with a transdermal miniaturized monitor recording the signal of
exogenous FITC-sinistrin in conscious mice. As few studies had used this technique and
analyzed GFR evolution in this model, GFR evolution in this model was closely examined.
Table 5.1 and Figure 5.8 A showed the effect of diabetes and uninephrectomy on the
evolution of GFR. First is the effect of diabetes on GFR. GFR in healthy wild type mice was
relatively stable from 8 to 26 weeks of age, which increasing gradually from 199.2 ± 21.6
µl/min to 274.6 ± 21.3 µl/min. Due to hyperglycaemia, obesity, and polyphagia, GFR in DM-2K
mice started with a twice higher level compared to their wild type controls (431.6 ± 58.3),
dramatically increased to the peak at 13 weeks of age (685.0 ± 106.5), and gradually
decreased to 422.7 ± 86.7 at 26 weeks of age, which was comparable to their baseline GFR
level. Next is the effect of uninephrectomy on GFR. Five weeks after surgery, db/dbmice with
uninephrectomy (DM-1K) had a GFR level equivalent to around two third, but not half, of that
in db/dbmice with sham sergery. The GFR level in DM-1K group gradually declined to 275.3 ±
52.4 at the age of 26 weeks, which was similar to that in age-controlled wild type control
(WT-2K) group.
For the treatment effect of anti-IL-1β onGFR, compared tomice receiving control IgG,mice
receiving anti-IL-1β IgG had indistinguishable GFR level after 4-week treatment but had a higher
GFR level after 8-week treatment (5.8 C). The difference was around 50 µl/min (334.3 ± 31.7
vs. 275.3 ± 52.4, p = 0.02).
Table 5.1: Evolution of glomerular filtration rate in db/dbmice.
Group
Age, weeks
8 13 18 22 26*
WT-2K 199.2 ± 21.6 239.3 ± 22.3 249.0 ± 58.2 274.5 ± 47.8 274.6 ± 21.3
WT-1K 190.2 ± 18.6 154.6 ± 17.4 169.6 ± 11.7 175.7 ± 16.9 202.7 ± 23.3
DM-2K 431.6 ± 58.3 685.0 ± 106.5 659.2 ± 180.8 405.1 ± 143.8 422.7 ± 86.2
DM-1K 407.8 ± 58.8 432.4 ± 128.3 442.1 ± 81.1 306.8 ± 78.2 275.3 ± 52.4
* Data represent as Mean ± SD. Mouse numbers for WT-2K, WT-1K and DM-2K were 5, 5, 8,
and 11. Mouse number for DM-1K was 20 from 8 weeks to 18 weeks , and 8-11 from for 22
to 26 weeks which was taken from DM-1K+IgG group.
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Excretory kidney function was also evaluated by BUN measurement. As demonstrated in
Figure 5.8 D, at the age of 26 weeks, mice from all groups had no significant difference in BUN.
When comparing BUN only between DM-1K+anti-IL-1β and DM-1K+IgG group, there was still
no between-group difference (Figure 5.8. Considering that GFR levels in diabeticmice were still
higher thanwild type controls at the age of 26 weeks, BUNmight not be an sensitive parameter
reflecting excretory kidney function.
Thus, anti-IL-1β IgG treatment in db/db mice with uninephrectomy preserves more GFR
than control IgG.
Figure 5.8: Effects of anti-IL-1β IgG treatment on kidney function in db/dbmice. A, GFR before treatment. GFR
was measured before treatment began (from 8 to 18 weeks of age). Uninephrectomy was performed shortly after
8 weeks old. ****p <0.0001 in a two-way ANOVA test. B, GFR after treatment. GFR was measure after treatment
started. C, GFR at the age of 26 weeks. Comparison was calculated by t test. D, BUN. E, BUN at 26 weeks of age.
GFR, glomerular fitlration rate.
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Figure 5.9: Effect of anti-IL-1β antibody on albuminuria in db/dbmice. A, UACR. Concentration of albumin and
creatinine in spot urine were determined by ELISA and Jaffe method, respectively. B, UCAR at 26 weeks of age.
UACR, urine albumin to creatinine ratio.
5.2.4 Effects of interleukin-1β blockade on proteinuria
Proteinuria is a critical parameter for kidney disease progress and a predictor for kidney
outcome. In the current study, albuminuria was measured by urine albumin ELISA normalized
to urine creatinine. The Time course of urinary albumin-creatinine ratio (UACR) during 8-week
treatment was shown in Figure 5.9 A. Mice receiving anti-IL-1β IgG treatment had similar
levels of UACR compared to those treated with control IgG after 4-week treatment and
8-weeks treatment (p = 0.49). Thus, anti-IL-1β IgG does not reduce urine albumin excretion in
db/dbmice with uninephrectomy.
5.2.5 Effects of interleukin-1β blockade on glomerular hypertrophy
From the onset of diabetes, glomeruli undergo hypertrophy, which is most likely an adaptive
response to hyperfiltration driven by hyperglycemia, SGLT2-induced tubuloglomerular
feedback disorder, and low nephron per body mass [141, 142]. In order to explore the
potential effect of anti-IL-1β treatment on glomerular hypertrophy, tuft and Bowman’s
capsule size was measured in 15-25 cortex glomeruli per kidney in PAS-staining slides. In
Figure 5.10 A, it showed representative images from each group. The size of glomerular tuft
(yellow dot line) and Bowman’s capsule (green line) was larger in DM-1K+IgG and
DM-1K+anti-IL-1β group.
The glomeruli from all the mice in each group were pooled, and a density plot was
generated to see the distribution of glomerular size in each group. As shown in Figure 5.10 B,
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compared with healthy wild type controls (WT-2K), wild type mice with uninephrectomy
(WT-1K) and diabetic mice showed a clear ”shift” towards bigger tuft, bigger Bowman’s
capsule, and higher tuft/capsule ratio. This phenomenon was more obvious in diabetic mice
with uninephrectomy (DM-1K+IgG and DM-1K+anti-IL-1β). The glomerular size distribution
did not differ between DM-1K+IgG and DM-1K+anti-IL-1β.
Then the average size was calculated and the results were shown in Figure 5.10 C.
Compared with IgG-treated mice, anti-IL-1β-treated mice displayed similar tuft area, capsule
area, and tuft/capsule ratio. Thus, anti-IL-1β treatment does not alter glomerular hypertrophy
in db/dbmice with uninephrectomy.
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5.2.6 Effects of interleukin-1β blockade on podocyte loss
In consequence of glomerular hyperfiltration and hypertrophy, glomerular filtration surface
expands and post-mitotic podocytes accommodating to remain attached to the filtration
membrane [142]. As glomerular hyperfiltration and hypertrophy persist, podocyte loss is
inevitable, underlining the progression of DKD. In order to see whether anti-IL-1β had an
effect on podocyte loss in db/db mice, we perform WT-1 staining in kidney sections (Figure
5.11 A) and counted glomerular WT-1 positive cells from 15-25 cortex glomeruli for each
kidney section (Figure 5.11 B).
Figure 5.10: Effect of anti-IL-1β antibody on glomerular size in db/dbmice. A, Tuft and Bowman’s capsule area in
PAS staining. Kidney sections were stained by PAS staining. Representative images of glomeruli from each group.
Yellow dash line, tuft area. Green dash line, Bowman’s capsule area. Original magnification 400x. B, Distribution
of glomerular size. Area of tuft and capsule, as well as tuft over capsule ratio from 10-25 glomeruli per mouse was
measured by software. Density plots were generated based on the pooled data from mice belonging to the same
group. Each vertical short line beneath the histogram represents for the value of one glomerulus. C, Quantification
of glomerular size. N.S., statistically not significant; *p <0.05; **p <0.005; ***p <0.001.
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The number of WT-1 positive cells per glomerulus in anti-IL-1β-treated mice was
significantly higher (11.8 ± 0.40) than IgG-treated mice (10.15 ± 0.27). WT-1/nephrin double
staining was further performed, which has a higher specificity for podocyte, to confirm the
result from WT-1 staining by the immunochemistry method. As shown in Figure 5.11 C, the
number of WT-1 and nephrin double positive cells per glomerulus in anti-IL-1β-treated mice
(10.72 ± 0.59) was significantly higher compared with IgG-treated mice (8.65 ± 0.35), which
was consist with the result fromWT-1 single staining.
For comparison of podocyte counts between other groups, WT-2K displayed significantly
more WT-1 positive cells (16.86 ± 0.60) than WT-1K (13.78 ± 1.86). DM-2K (13.60 ± 0.29) also
showed more WT-1 positive cells compared to DM-1K. Above indicates the effect of
Figure 5.11: Effect of anti-IL-1β antibody on podocyte loss in db/dbmice. A,WT-1 staining. Kidney sections were
stained for WT-1. Representative images of each group. Original magnification 400x. B, Quantification of WT-1
positive cells. One dot represented the mean of WT-1 positive cells calculated from 15-25 cortex glomeruli per
kidney section. C, WT-1/nephrin double staining. Original magnification 400x. D, Quantification of WT-1/nephrin
double positive cells. *p <0.05.
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compensatory hyperfiltration and podocyte loss secondary to uninephrectomy. WT-2K group
showed more WT-1 positive cells than DM-2K group; WT-1K group also showed more WT-1
positive cells compared to DM-1K+IgG. Above indicates the effect of diabetes on podocyte
loss.
To further evaluate the effects of anti-IL-1β treatment on podocyte loss, we performed RT-
qPCR to quantify the transcription levels of podocyte marker genes. As represented in Figure
5.11 D, compared with IgG-treated mice, IL-1β-treated mice showed a significant upregulation
of mRNA levels in Synpo andWt1 but not in .
Taken together, anti-IL-1β treatment ameliorates podocyte loss driven by diabetes and
uninephrectomy.
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Figure 5.12: Effect of anti-IL-1β antibody on podocyte marker gene expression in db/db mice. RNA expression
levels of podocyte markers in wild type mice and db/db mice with or without uninephrectomy. Kidney RNA was
isolated and measured for Synpo,Wt1, Nphs1, and Tjp1 expression levels by real-time quantitative PCR. N.S., not
significant; *p <0.05; **p <0.01; ***p <0.001.
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5.2.7 Effects of interleukin-1β blockade on kidney fibrosis
Kidney fibrosis is a hallmark of DKD. Collagen deposition in GBM and mesangium is the major
contribution to intra-glomerular fibrosis. In order to analyse kidney fibrosis, kidney slides
were stained with picro-sirius red to visualize the deposition of collagen type I and III. As
shown in Figure 5.13, DM-1K+IgG mice had greater picro-sirius red area than DM-2K group
(5.86 ± 0.48% vs. 1.49 ± 0.33%, p<0.05), indicating an effect of nephron loss in the context of
diabetes. Nevertheless, picro-sirius red area in glomerular compartment in anti-IL-1β group
was indistinguishable to control group. Besides, there was no significant difference between
DM-2K, WT-1K, and WT-2K.
Figure 5.13: Effect of anti-IL-1β antibody on glomerulosclerosis in db/dbmice. A, Picro-sirius red staining. Mouse
kidney sections were stained for Picro-sirius red staining, which indicates collagen deposition. Representative
pictures of glomeruli from each group. Original magnification 400x. B, Quantification of picro-sirius red. Results
were presented as the ratio of picro-sirius red positive area over glomerular tuft area. N.S., statistically not
significant; *p <0.05.
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αSMA is another source for tissue fibrosis. Next, kidney fibrosis was analyzed by αSMA
staining. As demonstrated in Figure 5.14 A, αSMA staining positive area located mainly in
arteries, interstitial fibrosis area, as well as in mesangial matrices. To rule out the confounding
factor from arteries, artery area was removed from the whole section and the remnant was
quantified. As shown in Figure 5.14 B, αSMA staining was similar across all groups;
DM-1K+IgG groups showed no increase in αSMA compared to healthy wild type mice (3.61%
± 0.39 vs. 2.80 ± 0.41%, p = 0.87), indicating αSMA deposition might be a later event in
current model compared with hypertrophy and podocyte loss.
Figure 5.14: Effect of anti-IL-1β antibody on kidneyα SMAaccumulation in db/dbmice. A, αSMA staining. Kidney
sectionswere stained for αSMA. Representative images of kidney sections fromeach group. Originalmagnification
100x. B, Quantification of αSMA staining. Result was calculated as the percentage of αSMA positive area over
kidney section (arteries area was omitted). N.S., statistically not significant.
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Gene expression of fibrosis components were alsomeasured to evaluate fibrosis levels. As
shown in Figure 5.15 A-C, anti-IL-1β IgG treatment significantly reduced Acta2 (gene encodes
αSMA) and Col4a3.
Taken together, the overall fibrosis level in current model is not pronounced at protein
level. Anti-IL-1β IgG reduces fibrosis-related gene expression in db/db mice with
uninephrectomy.
Figure 5.15: Effect of anti-IL-1β antibody on kidney fibrosis marker gene expressions in db/dbmice. Kidney was
analyzed for Acta2, Col1a1, and Col4a3mRNA expression by real-time quantitative PCR. Acta2 encodes αSMA. *p
<0.05; ***p <0.001.
5.2.8 Effects of interleukin-1β blockade on kidney inflammation
Kidney inflammation is a key event in DKD. In DKD, macrophages infiltrate into glomerular
compartment and promote local inflammation. To visualize infiltrated macrophages in
glomerular compartment, Mac-2 (galectin-3), a marker for macrophages, was stained and
quantified. As demonstrated in Figure 5.16, nephron loss in combination with diabetes in
DM-1K+IgG group (3.14 ± 0.40) induced a significantly greater number of infiltrated
macrophages compared to DM-2K (1.53 ± 0.21), WT-1K (1.33 ± 0.35), and WT-2K (0.63 ± 0.18).
Also, anti-IL-1β-treated mice had less Mac-2 positive cells compared to IgG control (1.74 ±
0.20 vs. 1.53 ± 0.21, p = 0.003).
To further analyze the inflammation levels, we performed RT-qPCR to examine the mRNA
expression levels of inflammatory genes. As shown in Figure 5.17, neither Il1b-related genes,
nor cytokine genes such as Il6 and Tgfb, nor chemokine genes such as Ccl2, Cx3cl1 and Ccl5,
was significant between anti-IL-1β-treated mice and IgG-treated mice.
Taken together, anti-IL-1β IgG treatment reduces the number of infiltrating macrophages
in diabetic mice compared with control group.
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Figure 5.16: Macrophage staining in mouse glomeruli. A, Mac-2 staining. Kidney sections were stained for Mac-
2. Representative images of glomerulus from each group. Original magnification 400x. B, Quantification of Mac-2
positive cells. Each dot represents themean ofMac-2 positive cells from15-25 cortex glomeruli per kidney section.
**p <0.01; ***p <0.001.
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Figure 5.17: Mouse kidney inflammatory gene expressions. A-D, Ilb-related mRNA expression. E-F, Cytokine Il6
and Tgfb expression. G-I, Chemokine Ccl2, Cx3cl1, and Ccr5 expression. Data represent relative gene expression
after log₁₀ transformation from each group. N.S., not significant; *p <0.05; **p < 0.01.
6 Discussion
We had hypothesized that:
1. An oxalate-rich diet could induce crystal deposition and GFR loss in db/dbmice.
2. IL-1β blockade by a specific anti-IL-1β IgG would have renoprotective effects in a mouse
model of DKD.
Testing these hypotheses experimentally gave the following results:
1. Oxalate-rich diet did not induce GFR deterioration on C57BL/Ks db/db mice because
oxalate-rich diet did not lead to significant nephrocalcinosis.
2. Kidney IL-1β expression is induced in DKD. Specific blockade using an anti-IL-1β IgG did
not alter glucose homeostasis. IL-1 blockade by anti-IL-1β IgG had statistically significant
renoprotective effects on GFR, podocyte loss, fibrosis, and macrophage infiltration with
a minor to moderate effect size but not on albuminuria or BUN levels.
6.1 Oxalate-rich diet does not induce crystal formation and GFR loss in db/dbmice
Oxalate-rich food did not induce GFR loss and crystal deposition in kidneys of db/db C57BL/Ks
mice, as reported from C57BL/6N mice [76, 77, 78, 79, 80, 81, 82]. One possible explanation
is that this model is strain dependent. Marschner J.A., et al found that oxalate-rich
diet-induced nephrocalcinosis and CKD was restricted to certain gender of certain mouse
strains. For instance, both genders of C57BL/6N and male Balb/c mice were prone to develop
mass crystal deposition in kidney upon oxalate-rich diet, while female Balb/c mice and both
genders of CD-1 and 129SV mice was resistant to crystal deposition [82]. As mention before,
C57BL/Ks carries ≈84% C57BL/6J-like and ≈14% DBA/2J-like alleles [70]. Another possible
explanation is the osmotic diuresis in hyperglycemic db/db mice with the consequence of
urine dilution, which might also lead to reduced crystal deposition in kidney. We decided not
to perform a deeper analysis into the underlying causes, as obviously this approach turned
out to be not useful to replace uninephrectomy to accelerate DKD in db/db C57BL/Ks mice.
6.2 Immune cells are the main source of interleukin-1β in diabetic kidneys
Previous studies have shown increased IL-1β gene expression by microarray [38] and
increased IL-1β protein expression by immunohistology [118] in kidney biopsies from patients
with diabetes. By analyzing the micro-dissected glomeruli and interstitium tissues from
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diabetic patients, we found IL1B expression levels increased in both tissue compartments
compared to healthy humans, which supports the previous finding that in human DKD IL-1β
was significantly induced [38, 118]. As with human kidney, an enhanced IL-1β expression in
both gene and protein levels was found in the db/db mouse model of DKD, which is also
consistent with results reported by others using the same or other mouse models of DKD [38,
111, 118].
The cellular origin of IL-1β expression in DKD is not fully clear [115]. Even though
immune cells are well-known to express IL-1β [88, 83, 90], there are debates on whether also
kidney parenchymal cells can express IL-1β [87]. In vitro studies have shown IL-1β protein
expression in response to various stimuli in several kidney cells, e.g. a human podocytes cell
line [38], primary mouse podocytes [38], primary mouse glomerular endothelial cells [38],
primary mouse collecting duct epithelial cells [112], and primary mouse proximal tubular cells
(cell line [113], primary [114]). However, other studies performed on podocytes [143],
pericytes [144], glomerular endothelial cells [144], tubular epithelial cells [145] did not detect
production of mature IL-1β upon exposure to inflammasome-activating stimuli. According to
a recent single-nucleus RNA-sequencing dataset of human DKD, IL1B expression was found in
1-2% of leukocytes, ≈0.5% of mesangial cells, <0.5% of epithelial cells in proximal convoluted
tubule, ≈0.5% of epithelial cells in distal convoluted tubule, <0.5% of endothelial cells, and
<0.5% of type A intercalated cells. Almost no podocytes tested expressed IL1B. Furthermore,
kidney parenchymal cells expressed IL1B in a lesser extent than leukocytes [31]. In our
immunostaining results, IL-1β was mainly expressed in infiltrated cells in both glomeruli and
interstitium, most probably mononuclear phagocytes [146, 26], and occasionally expressed in
tubular epithelial cells. Our results do not support endothelial cells or podocytes as
IL-1β-expressing cells.
IL-1β expression can derive from inflammasome-dependent and -independent pathways
[94]. Of various inflammasomes, NLRP3-inflammasome is the most characterized one [115].
We found NLRP3 was highly and diffusely expressed in tubular epithelial cells in human DKD.
To a lesser extent, NLRP3 was expressed in infiltrated cells in interstitium, in glomerular
parietal epithelial cells, and in glomerular cells, especially those closed to vascular pole. As
infiltrated cells expressed both NLRP3 and IL-1β, one presumption could be that
NLRP3-inflammasome dependent IL-1β is activated in infiltrated cells. However, a co-staining
of IL-1β and NLRP3, or inflammasome-associated speck-like structure is needed to confirm
such presumption [115]. Another notable observation from the human immunohistology is
that, the abundance of NLRP3 and meanwhile absent of IL-1β expression in non-myeloid cells,
e.g. most tubular epithelial cells and glomerular cells, indicate an IL-1β-independent role of
NLRP3 in human DKD. Consisting with this observation, a previous study showed tubular cells
did express NLRP3, ASC, and pro-caspase 1 but did not release IL-1β after canonical
inflammasome stimuli. Instead, NLRP3 assembled a speck-like structure together with ASC
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and caspase 8 in mitochondria during TNFα/cycloheximide induced apoptosis in proximal
tubular epithelial cells [145]. Another study also indicated IL-1-independent role of NLRP3 in
nephrocalcinosis-related CKD, including development of pro-inflammatory and -fibrotic
phenotype in macrophages in vivo, and TGFβ-dependent fibrosis and proliferation in primary
murine fibroblasts in vitro [78]. Considering the diffuse NLRP3 expression in kidney from
diabetic patients, as well as kidney protective phenotypes from diabetic Nlrp3-/- mice [38],
more research on the IL-1β-independent role of NLRP3 in DKD is needed.
6.3 Interleukin-1β blockade has moderate renoprotective effects
Treatment with the anti-IL-1β antibody preserved higher GFR in uninephrectomized db/db
mice, indicating IL-1β is involved in kidney function decline in diabetes. The underlying
mechanism might involve anti-IL-1β antibody blocking IL-1β-related kidney inflammation,
fibrosis, and podocyte loss.
Firstly, the levels of various inflammation markers were reduced in diabetic kidneys
treated with anti-IL-1β antibody such as macrophage inside glomeruli. Macrophage
infiltration is a hallmark of inflammation in DKD. Fiona C, et al. characterized infiltrated
macrophages in db/+, db/db mice at the age of 2 months, and db/db mice at the age of 8
months. They found glomerular macrophage infiltration correlated with albuminuria,
glomerular hypertrophy, glomerular collagen IV accumulation. The number of infiltrated cells
correlated with kidney gene expression of chemokines, e.g. Ccl2, Spp1, Mif, and Csf1 [147].
Transcription levels of Ccl2, Ccl5, and Cx3cl1 were measured in my study due to they are
considered as the most important chemokines attracting macrophages in diabetic kidney
disease [27, 148]. However, we did not find anti-IL-1β treatment reduced these gene
expression in kidneys, indicating less infiltration of macrophage by anti-IL-1β antibody could
be chemokine-independent. Non-kidney-related mechanism might be involved, e.g. in bone
marrows, IL-1β is a mediator of promoting hematopoiesis through mechanisms such as
increasing production of hematopoietic growth factors and regulating proliferation of
primitive hematopoietic progenitor cells [149].
Second, anti-IL-1β antibody treatment reduced fibrosis. In IL-1β immunostaining of
diabetic patients, IL-1β staining intensity correlated with kidney interstitial fibrosis and
tubular atrophy, indicating IL-1β is associated with fibrosis. Indeed, a recent study revealed a
mechanism by which IL-1β drives kidney fibrosis [43]. The authors found taht stimulation of
IL-1β in kidney stromal cells resulted in an interleukin 1 receptor associated kinase
4-dependent activation of MYC, which is a transcription factor regulates genes of glycolysis,
proliferation, and fibrosis. Inhibition of IL-1β downstream signaling, interleukin 1 receptor
associated kinase 4 and MYC, resulted in less fibrosis in mice and in kidney organoids in vitro
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[43]. Consistent with this study, we found reduced expression levels of fibrosis genes, e.g.
Acta2, Col1a1, Col4a1 in diabetic mice receiving anti-IL-1β treatment, which was likely the
result from blocking IL-1β-induced fibrosis. However, we did not find difference in αSMA
staining or collagen staining between control and treatment group, one possible explanation
could be the overall fibrosis level was relatively low in this model. Whether IL-1β blockade
can reduce overt kidney fibrosis needs further study in models with more advanced diabetic
kidney disease, like eNOS−/− db/dbmice.
Third, inhibition of IL-1β had a protective effect on podocyte loss. Mice receiving
anti-IL-1β IgG treatment exhibited less podocyte loss as indicated by two independent
immunostainings and higher gene expression levels of podocyte markers. IL-1R1 and IL1RAP
are ubiquitous expressed on almost all cells and the latter is necessary for IL-1β signaling [87,
116]. Interestingly, according to single-nucleus RNA-sequencing dataset of human DKD [31],
≈40% and 20-30% glomerular parietal epithelial cells expressed IL1R3, in contrast only less
than 10% endothelial cells and mesangial cells expressed IL1R3, suggesting that podocytes
and glomerular parietal epithelial cells might be the major targets in glomeruli in response to
IL-1β. The benefits of anti-IL-1β antibodies on podocyte loss might be associated with IL-1β
neutralization and thus less IL-1β-IL-1R1-IL-1R3 complex formation on podocytes. But in our
study, a higher number of podocyte in anti-IL-1β treated mice did not lead to a lower
albuminuria level. The number of podocyte per glomerulus is one of the various structural
parameters in DKD [150]. The correlation between glomerular structure alterations and
function changes have been investigated in patients with T1D and t2d [151, 150, 152]. Meyer
T.W., et al. analyzed biopsies from 16 American Indian with T2D and found that the podocyte
number was tightly associated with albuminuria progression [150]. On the contrary, another
study analyzed the correlation between kidney functional parameters (GFR and albuminuria)
and kidney structural alterations in 48 diabetic American Indian patients with GFR > 90
mL/min/1.73m². These patients were followed up for around 9 years on average. The authors
found that albuminuria progression was positively correlated with mesangial expansion,
glomerular volume, GBM thickening, surface density of GBM, and glomerulosclerosis but not
correlate with podocyte density [152]. Above studies suggested that podocyte number
measured by two-dimensional method in present study could only partially explain
albuminuria. Other structural alterations, like glomerular collagen deposition, αSMA
accumulation, and glomerular size, which were similar between control group and anti-IL-1β
antibody treated group, might also be associated with albuminuria progress and probably
lead to a similar albuminuria level between these two groups.
Shahzad K, et al. also tested IL-1β blockade in DKD models. The authors treated db/db
mice at the age of 8 weeks and 12 weeks with anakinra. The treatment lasted for 12 weeks
and 8 weeks, respectively. The authors found that anakinra normalized albuminuria and
mesangial expansion in above two study designs [38]. In present study, we did not find as
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potent protective effects on albuminuria and mesangial expansion from anti-IL-1β in diabetic
mice. The possible explanations are as follows. First, at the treatment initiation severity levels
of DKD were different in these two studies. In study from Shahzad K. et al., treatment started
in 8- and 12-week-old db/db mice, whereas in current study treatment started in
uninephrectomized db/db mice at the age of 18 weeks. Second, treatment lasted 12 and 8
weeks in study from Shahzad K, et al.. In present study it lasted 8 weeks. Third, anakinra
exhibited kidney protection, indication the effects could be IL-1β- or/and IL-1α- dependent,
while in our study, protection effects was only IL-1β specific. Nevertheless, it indicates that
IL-1β contributes to kidney structural and functional changes since the early phase of DKD
[38]. Thus, a preemptive and extended treatment might be needed to achieve better kidney
outcomes.
6.4 Interleukin-1β blockade does not alter glucose homeostasis
From the previous literature, a glucose-lowering effect of IL-1β blockade was uncertain in
patients with T2D, as shown in Table 1.3. For instance, treatment with IL-1β/IL-1R blockade
induced a decrease [121, 122, 131], or an increase [127], or no change [124, 123] on HbA1c in
patients with T2D. Similarly, animal models of diabetes or obesity also found inconsistent
results. For instance, IL-1β/IL-1R blockade induced a decrease [153, 154, 155, 156, 157], or no
change [158, 159] in blood glucose levels.
Many studies have unveiled how IL-1β affects glucose homeostasis. On one hand, IL-1β
might be a mediator inducing β cell impairment and reducing insulin secretion [160, 161].
Boeni-Schnetzler M, et al. found that IL-1β can induce β cell dysfunction via the E2F1-Kir6.2
pathway. In mouse isolated islets, IL-1β suppressed the expression of Kir6.2, which is a
potassium channel and regulates insulin secretion in β cells. The IL-1β-dependent
downregulation of Kir6.2 was partially through E2F1, a transcription factor not only regulates
cell cycle but also Kir6.2 [162]. On the other hand, IL-1β can induce insulin release by
pancreatic islets ex vivo [163]. It can also increase serum GLP1 levels, resulting in
hyperinsulinemia and hypoglycemia [164]. Similarly, a recent study found that
macrophage-derived IL-1β is a physiological mediator in postprandium-induced insulin
secretion [165]. In this study Dror E, et al. found that postprandial hyperglycemia can induce
primed-macrophages releasing IL-1β. This activation and secretion of IL-1β was
NLRP3-dependent. The postprandium-related IL-1β promoted β cells to secrete insulin. In
turn, secreted insulin acted on macrophages via insulin recetpors and induced glucose
uptake, IL-1β secretion, and ROS production. In contrast, Il1b deficient mice had impaired
insulin secretion after feeding [165]. This study revealed a physiological role of IL-1β in
glucose homeostasis that it acts as a mediator to mobilize glucose disposal after meals and
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specifically fuel macrophages [166]. Together, IL-1β can have opposite roles on regulating
glucose homeostasis.
In the present study, IL-1β blockade did not affect blood glucose levels. Further
measurements could provide mechanistic insights, such as glucose tolerance test or insulin
secretion but our animal clearance did not include a permission for these kinds of analyses.
6.5 Limitations
There are several limitations in the present study. Firstly, our db/db model with
uninephrectomy still did not display advanced CKD. Though diabetic mice with
uninephrectomy had ≈50 times higher albuminuria level compared to healthy wild type
controls and ≈40% less GFR compared to their peak values. When the treatment finished,
diabetic mice with uninephrectomy still had comparable GFR level compared to healthy
controls. Further, fibrosis and glomerulosclerosis were not evident at the study end, which
caused difficulty to evaluate the efficacy of anti-IL-1β on fibrosis and sclerosis. Thus, this
model could only represent the disease scenario before CKD G3a. Second, our group size was
relatively small, resulting in less power to detect the difference between each group,
especially when comparing parameters with big variations, such as albuminuria. Third, the
IL-1β biological activity upon anti-IL-1β antibody injection was not determined. We were not
able to detect the pharmacokinetic profile of anti-IL-1β IgG in circulation or in kidney, which
could be measured by mass spectrometry approaches [167]. Fourth, spot urine, but not
24-hour urine collected by metabolic cages, was used. Even though it was calibrated by
creatinine levels, bias may still exist. Fifth, we measured podocyte loss basing on
two-dimension images, which is a suboptimal approach [168]. Sixth, we lacked oxalate
measurement in urine or serum to explore the causes of no crystal deposition in kidney.
7 Summary
An animal model with overt DKD is needed for preclinical study. Uninephrectomy is a
common tool to accelerate kidney impairment but it has shortcomings such as lethality and
kidney infection. Given that oxalate-rich diet is a convenient method to generate progressive
nephrocalcinosis, tubular atrophy, and CKD in C56BL6 mice, we want to explore the possibility
of using oxalate-rich diet as a substitutive and non-surgical approach to accelerate kidney
impairment in db/db. We fed db/dbmice of 14 weeks old with oxalate-rich diet or control diet
for 30 days. We measured GFR every 10 days and analysed the crystal deposition in kidney
after 30 days. We found that oxalate rich diet did not induce GFR loss and oxalate crystal
deposition in kidney compared to mice with control diet.
Inflammation is one of the center mechanisms leading to DKD. Infiltrated immune cells as
well as renal resident cells release various cytokines which contribute to kidney function loss
and structural alterations. Of the cytokines, IL-1β is a key mediator in amplifying inflammation,
such as upregulating chemokines and other cytokines. IL-1β also contributes to kidney fibrosis.
Thus IL-1β serves as a potential target for DKD.
Previous studies have shown that NLRP3-dependent IL-1β from non-myeloid cell
contribute to initiation and progression of DKD in diabetic mice, even though other studies
suggested that non-myeloid cells may lack the ability to synthesis IL-1β. Our first aim was to
investigate IL-1β expression and possible cellular location in kidney. We observed IL-1β
expression was mildly increased in kidney biopsies from patients with diabetes at protein and
mRNA level, as indicated by immunostaining and microarray, respectively. In a
uninephrectomized db/dbmice, IL-1β gene expression level was also increased. Furthermore,
human biopsy immunostainings demonstrated that IL-1β was mainly located in infiltrated
immune cells. Therefore, IL-1β expression was induced in DKD and was mainly expressed by
immune cells.
Since we observed IL-1β expression is increased in DKD, we hypothesized that targeting
IL-1β has a renal protective effect on DKD in animal model of DKD. To test this hypothesis, we
treated 18-week-old db/db mice undergoing uninephrectomy at the age of 8 weeks with
anti-IL-1β IgG antibody or control IgG for 8 weeks. Mice treated with anti-IL-1β IgG preserved
higher glomerular filtration rate but comparable albuminuria level to those treated with
control IgG. On glomerular structural changes, anti-IL-1β antibody treatment did not affect
glomerular tuft and Bowman’s capsule size, nor collagen deposition in glomeruli. However,
anti-IL-1β showed higher podocyte account and higher expression levels of podocyte marker
genes. IL-1β blockade also reduced infiltrated macrophages in glomeruli. On fibrosis, IL-1β
blockade did not reduced alpha smooth muscle actin accumulation, but reduced fibrosis gene
expression, such as Acta2 and Col4a3.
In conclusion, (i) oxalate-rich diet did not induce massive oxalate crystal deposition in
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kidney nor GFR loss, thus is not a suitable method to generate overt DKD in db/db model. (ii)
kidney IL-1β expression mildly increased in human diabetes, and mainly originated from
immune cells. Targeting IL-1β by antibody generated a moderate effect on glomerular
filtration rate decline, podocyte loss, and renal inflammation in type 2 diabetic mice with CKD.
Whether these findings can translate into better outcomes also in human DKD remains to be
determined.
8 Zusammenfassung
In der präklinischen Forschung besteht der nicht erfüllte Bedarf nach einem Tiermodell für
schwere diabetische Nephropathie. Die Uninephrektomie ist ein gebräuchliches Mittel zur
Beschleunigung der Nierenschädigung, hat jedoch Mängel wie Letalität und
Niereninfektionen. Angesichts der Tatsache, dass eine oxalatreiche Ernährung eine geeignete
Methode ist, um progressive Nephrokalzinose, tubuläre Atrophie und chronische
Nierenerkrankung bei C56BL6-Mäusen zu induzieren, wollen wir die Möglichkeit untersuchen,
oxalatreiche Ernährung als substitutiven und nicht-chirurgischen Ansatz zur Beschleunigung
der Nierenschädigung im db/db-Modell einzusetzen. Db/db-Mäuse im Alter von 14 Wochen
wurden 30 Tage lang mit oxalatreicher Nahrung bzw. einer Kontrolldiät gefüttert. Die
glomeruläre Filtrationsrate wurde alle 10 Tage, Kristallablagerungen in der Niere nach 30
Tagen bestimmt. Die Ergebnisse zeigten, dass oxalatreiches Futter im Vergleich zur
Kontrolldiät keinen GFR-Verlust und keine Oxalatkristallablagerung in der Niere induzierte.
Die Entzündung ist einer der zentralen Mechanismen, die zu einer diabetischen
Nephropathie führen. Infiltrierte Immunzellen sowie nierenresidente Zellen setzen
verschiedene Zytokine frei, die zum Verlust der Nierenfunktion und zu strukturellen
Veränderungen beitragen. Unter den Zytokinen ist IL-1b ein Schlüsselmediator bei der
Verstärkung der Entzündung, wie z.B. durch die Hochregulierung von Chemokinen und
anderen Zytokinen. IL-1b trägt auch zur Nierenfibrose bei. Somit stellt IL-1b ein potentielles
therapeutisches Ziel bei diabetischer Nephropathie dar.
Vorangegangene Studien haben gezeigt, dass NLRP3-abhängiges IL-1b aus
nicht-myeloiden Zellen zur Auslösung und zum Fortschreiten einer diabetischen
Nephropathie in diabetischen Mäusen beiträgt, obwohl andere Studien darauf hindeuteten,
dass nicht-myeloide Zellen möglicherweise nicht die Fähigkeit zur Synthese von IL-1b besitzen.
Das erste Ziel der vorliegenden Studie war daher die Untersuchung der IL-1b-Expression und
seiner möglichen zellulären Lokalisation in der Niere. Es zeigte sich, dass die IL-1b-Expression
in Nierenbiopsien von Patienten mit Diabetes auf Protein- und mRNA-Ebene leicht erhöht
war, wie durch Immunfärbung bzw. Microarray gezeigt werden konnte. In
uninephrektomierten db/db-Mäusen war die IL-1b-Genexpression ebenfalls erhöht. Darüber
hinaus zeigten Immunfärbungen in menschlichen Biopsien, dass IL-1b hauptsächlich in
infiltrierten Immunzellen lokalisiert war. Daraus kann geschlussfolgert werden, dass die
IL-1b-Expression bei diabetischer Nephropathie hauptsächlich in Immunzellen induziert wird.
In Anbetracht der Tatsache, dass IL-1b bei der diabetischen Nephropathie erhöht
exprimiert ist, sollte nachfolgend die Hypothese überprüft werden, dass die gezielte
Inhibierung von IL-1b im Tiermodell der diabetischen Nephropathie einenprotektiven renalen
Effekt auf aufweist. Hierzu wurden 18 Wochen alte db/db-Mäuse, die im Alter von 8 Wochen
einer Uninephrektomie unterzogen wurden, 8 Wochen lang mit Anti-IL-1b-IgG-Antikörpern
bzw. Kontroll-IgG behandelt. Mit Anti-IL-1b-IgG behandelte Mäuse zeigten im Vergleich zu
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den Kontroll-IgG behandelten Mäusen eine höhere glomeruläre Filtrationsrate, aber eine
vergleichbar ausgeprägte Albuminurie. Im Hinblick auf glomeruläre Strukturveränderungen
beeinflusste die Behandlung mit Anti-IL-1b-Antikörpern weder die Größe des glomerulären
Kapillarknäuls und der Bowman’schen Kapsel noch die Kollagendeposition in den Glomeruli.
Die Behandlung mit Anti-IL-1b-Antikörpern führte jedoch zu einem geringeren
Podozyten-Verlust und einer höheren Expressions von Podozyten-Markergenen. Die
IL-1b-Blockade reduzierte auch die Zahl infiltrierter Makrophagen in den Glomeruli. Im
Hinblick auf fibrotische Veränderungen verringerte die IL-1b-Blockade nicht die Ablagerung
von Alpha-Aktin-2 , dafür aber die Expression von Fibrose-Markergenen wie Acta2 und
Col4a3.
Zusammenfassend lässt sich festhalten, dass (i) oxalatreiche Ernährung weder eine
massive Oxalatkristallablagerung in der Niere noch einen Verlust der glomerulären
Filtrationsrate induzierte und somit keine geeignete Methode ist, um eine schwere
diabetische Nephropathie im db/db-Modell zu erzeugen. (ii) Die IL-1b-Expression in der Niere
war bei Diabetes im Menschen leicht erhöht und stammte hauptsächlich von Immunzellen.
Die gezielte Beeinflussung von IL-1b durch Antikörper erzeugte eine moderate Wirkung auf
den Rückgang der glomerulären Filtrationsrate, den Podozytenverlust und die
Nierenentzündung bei diabetischen Mäusen vom Typ 2 mit chronischer Nephropathie. Ob
diese Ergebnisse auch auf die diabetische Nephropathie im Menschen übertragen werden
können, muss erst noch untersucht werden.
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BUN blood urea nitrogen.
CKD chronic kidney disease.
CT cycle threshold.
DAMPs danger-associated molecular patterns.





GBM glomerular basement membrane.
GFR glomerular filtration rate.
GLP1 glucagon-like peptide 1.
HbA1c hemoglobin A1C.
hsCRP high-sensitivity C-reaction protein.
IFTA interstitial fibrosis and tubular atrophy.
IL-1R1 IL-1 receptor type I.
IL-1R2 IL-1 receptor type II.
IL-1Ra interleukin-1 receptor antagonist.
IL-1α interleukin-1α.
IL-1β interleukin-1β.
IL1RAP IL-1 receptor accessory protein.
KFRT kidney failure with replacement therapy.
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KRT kidney replacement treatment.
LPS lipopolysaccharide.
NF-κB cytokine-dependent nuclear factor kappa-light-chain-enhancer of activated B cells.
NLRP3 nucleotide-binding domain and leucine-rich repeat pyrin containing protein-3.
PAMPs pathogen-associated molecular patterns.
PBMCs peripheral blood mononuclear cells.
PRRs pattern recognition receptors.
ROS reactive oxygen species.
SD standard deviation.
SGLT sodium-glucose cotransporter.
SGLT2i sodium-glucose cotransporter 2 inhibitors.
STZ streptozotocin.
T1D type 1 diabetes.
T2D type 2 diabetes.
TIR Toll-IL-1 resistance.
TLR Toll-like receptor.
TNFα tumor necrosis factor α.
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